Drug, bio-affecting and body treating compositions inventions

20090280055 - Use of fluorine-containing compounds for diagnostic purposes using imaging methods: Use of fluorine-containing compounds for the diagnostic detection of inflammatory processes by means of an imaging method, said inflammatory processes being selected from the group consisting of inflammatory processes of the lymphatic system, such as cancers that directly affect the lymph nodes, especially Hodgkin's disease, non-Hodgkin lymphomas, tumor metastases; liver... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090280056 - Antibodies and immunoconjugates and uses therefor: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.... Agent: Ginger R. Dreger, Esq. Goodwin Procter LLP

20090280057 - Combination of intercalating organometallic complexes and tumor seeking biomolecules for dna cleavage and radiotherapy: The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic... Agent: Mallinckrodt Inc.

20090280058 - Delivery of double-stranded rna into the central nervous system: The present invention provides for compositions and methods for in vivo delivery of a cell-permeable complex to cells of the central nervous system, wherein the cell-permeable complex decreases the level of a functional target protein encoded by a target mRNA molecule. In preferred embodiments of the invention, the cell-permeable complex... Agent: Baker Botts L.L.P.

20090280059 - Substituted aryl piperidinylalkynyladenosines as a2ar agonists: e

20090280061 - Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N—CH2COCH2-CH2CO—OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms;... Agent: Kenyon & Kenyon LLP

20090280060 - Photochromic probes: The present invention provides photochromic compounds and derivatives thereof as shown in claim 1 and methods of use of these compounds and derivatives. The present invention also provides photochromic optical probes capable of undergoing light directed reversible transition between a first state and a second state. The invention also teaches... Agent: Quarles & Brady LLP

20090280062 - Longevity-promoting effects of acetic acid and reishi polysaccharide: A composition of acetic acid and a composition of acetic acid and RF3 effecting expression of DAF-16 in C. elegans, wherein the at least acetic acid and the RF3 polysaccharide is effective to increase the life-span of C. elegans or humans. A method of regulating DAF-16 expression, comprising: administering a... Agent: Luce, Forward, Hamilton & Scripps LLP

20090280063 - Novel pei-peg graft copolymer coating of iron oxide nanoparticles for inflammation imaging: A nanostructure includes a nanoparticle core (110) and a ligand (120) bonded to the nanoparticle core (110). The ligand includes a linking group (130) having a first end bonded to a polyethylene imine (PEI) polymer (140) and a second end bonded to the nanoparticle core (110) and a polyethylene glycol... Agent: General Electric Company Global Research

20090280064 - Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans: A method and a device are disclosed for transdermal delivery to an animal or human of biological cargo-laden nanoparticles. The particles may include multimodal optical molecular imaging probes. The particles may be delivered by providing them in a form that can be absorbed through the skin and applying them to... Agent: Susan L. Parulski Patent Legal Staff

20090280065 - Uses and compositions for treatment of psoriasis: The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the... Agent: Mccarter & English, LLP Boston

20090280067 - Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone monohydrochloride: Crystal form E of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090280066 - Methods and compounds for the treatment of mucus hypersecretion: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the... Agent: Morris Manning Martin LLP

20090280068 - Polymorph of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone monohydrochloride: Crystal form D of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090280069 - Proguanil to treat skin/mucosal diseases: Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro-organisms. For example, when applied topically, proguanil is particularly effective against Propionibacterium acnes, a bacteria that causes acne; Corynebacterium minutissimum, a bacteria that causes erythrasma, Gardnerella vaginalis, a bacteria that causes vaginosis; Trichomonas vaginalis,... Agent: Schwegman, Lundberg & Woessner, P.A.

20090280070 - Chewing gum comprising hydroxyapatite: The present invention relates to a chewing gum comprising at least one gum base system, at least one chewing gum additive, and further comprising rod-shaped apatite crystals of the formula Ca5(PO4)3(OH)xFy having a length-to-breadth ratio of the crystals of at least ≧5.... Agent: The Nath Law Group

20090280071 - Use of repeat sequence protein polymers in personal care compositions: A personal care composition is provided and includes an effective amount of a repeat sequence protein polymer. The personal care composition may be a hair care composition, a skin care composition, a nail care composition, a cosmetic composition, or an over-the-counter pharmaceutical composition.... Agent: Dinsmore & Shohl LLP

20090280072 - Oral stain remover and oral composition: An oral stain remover which can remove a stain or a dental plaque effectively without a need of brushing the surface of teeth with a toothbrush or the like, and an oral composition containing the stain remover. An oral stain remover contains a salt of ultraphosphoric acid, and an oral... Agent: Birch Stewart Kolasch & Birch

20090280078 - Cosmetic composition to accelerate repair of functional wrinkles: A cosmetic composition consists of a combination of peptides that regenerate the dermal matrix and a rapid acting muscle relaxant derived from the extract of the plant, Acmella oleracea. By limiting cutaneous deformation caused by the contraction of facial muscles the extract increases the efficiency of the peptides in reducing... Agent: Robert M Skolnik

20090280076 - Cosmetics having excellent usability and stability and a method for making the same: c

20090280077 - Cosmetics having excellent usability and stability and a method for making the same: The cosmetic of the present invention is characterized in that it comprises an amino acid oil gelling agent, a polyamide resin and one or more monoesters selected from a monoester having a C9 to C24 linear chain or branched chain fatty acid residue and/or a C9 to C24 linear chain... Agent: The Harris Firm

20090280075 - Method for increasing the sun protection factor of a cosmetic and/or dermatological preparation: The present invention relates to a method of increasing the sun protection factor of a cosmetic and/or dermatological preparation, to the use of UV-A filters for increasing the sun protection factor of such a preparation and to specific photoprotective cosmetic and/or dermatological preparations.... Agent: Connolly Bove Lodge & Hutz, LLP

20090280073 - Method of enhancing deposition of benefit agents and providing and/or enhancing associated benefits: The invention relates to a method of enhancing/providing deposition of benefit agents using substantially surfactant free gel compositions comprising these hydrophobic and hydrophilic benefit agents. The method provides or enhances benefits associated with the benefit agents.... Agent: Unilever Patent Group

20090280074 - Use of glycyrrhetic acid and/or glycyrrhizin for producing cosmetic preparations for tanning the skin: The use of glycyrrhetin and/or glycyrrhizin for producing cosmetic or dermatological formulations for enhancing natural skin browning.... Agent: Greenblum & Bernstein, P.L.C

20090280079 - Composition and uses thereof: Use of a composition comprising oil bodies in the preparation of a formulation for administration to a mammal wherein said composition comprises oil curd 5 extracted from grain plant tissue, said oil curd comprising an aqueous dispersion of oil bodies and associated extrinsic protein material. Preferably, the oil curd is... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090280080 - Aryl silicone polyester resins as hair glossers: The present invention relates to a series of novel silicone polyesters which are prepared by crosslinking an aryl dimethicone copolyol with a dimer acid. The reaction of the aryl dimethicone copolyol and dimer acid results in a polyester having affinity to oils and provides outstanding gloss on hair.... Agent: Anthony J. O' Lenick, Jr.

20090280083 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090280081 - Jak/stat pathway inhibitors and uses thereof: The role of the JAK/STAT signal transduction pathway cellular mechanisms that lead to the onset and progression of degenerative joint diseases or disorders such as osteoarthritis (OA) is disclosed. Certain known effective OA therapeutics such as hymenialdisine, debromohymenialdisine, and its variants and derivatives are shown to function as JAK3-specific inhibitors,... Agent: Genzyme Corporation Legal Department

20090280082 - Methods for treating autoimmune disorders: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune... Agent: Morrison & Foerster LLP

20090280085 - Long acting human interferon analogs: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have... Agent: Yi Li

20090280086 - Methods and compositions for treating hepatitis c virus: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.... Agent: Jones Day

20090280084 - Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections: A method and composition for treating a host infected with a Caliciviridae virus, such as a Norovirus, comprising administering an effective treatment amount of a described modified nucleoside or a pharmaceutically acceptable salt thereof, is provided.... Agent: Intellectual Property / Technology Law

20090280087 - Interferon alpha and c-phycocyanin for the treatment of autoimmune diseases, allergy and cancer: The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-α/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for... Agent: Hoffmann & Baron, LLP

20090280089 - Inhibition of the liver tropism of adenoviral vectors: The invention relates to the inhibition of liver tropism of adenoviral vectors, by replacement of the endogeneous HVR5 of hexon protein of said adenoviral vector with an heterologous polypeptide.... Agent: Morgan Lewis & Bockius LLP

20090280088 - Method of controlling hair shape: The present invention provides a method for determining or modulating hair morphology and properties of natural wavy and frizzy hair and a method for evaluating or selecting a hair morphology modulator. The present invention provides a method for modulating hair morphology, including controlling an expression of IGFBP-5 gene or IGFBP-5... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090280090 - Methods of treating pigs with bacillus strains: Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration... Agent: Whyte Hirschboeck Dudek S.c. Intellectual Property Department

20090280091 - 5-fluorouracil-resistant bacteria and method for production thereof: The present invention provides a method for producing a cytosine deaminase (CD)-expressing, 5-fluorouracil (5-FU)-resistant microorganism which can grow in anaerobic tumor tissues, can express CD, and has a resistance to 5-FU at a concentration that is at least effective for antitumor activity. More specifically, the method is a method (A)... Agent: Jones Day

20090280098 - Composition for beverage or food: It is an object of the present invention to provide a composition for a food or beverage containing a butyric acid bacterium which produces butyric acid and is excellent in intestinal regulation and cellooligosaccharide which serves as a substrate for the butyric acid bacterium and facilitates the production of butyric... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090280099 - Nasopharyngeal inoculate of probiotics and prebiotics for treatment of respiratory infections: The present invention is directed to compositions comprising one or more species of probiotic bacteria, optionally in combination with one or more prebiotics, to methods of preventing and treating respiratory infections in animals by employing such compositions, and to methods of preparing the same.... Agent: King Pharmaceuticals, Inc.

20090280095 - Cell culture of keratinocytes under non-differentiating conditions: The present invention relates to a cell culture medium comprising (a) an inhibitor of bone morphogenetic protein-4 (BMP-4) and (b) an inhibitor of pigment epithelium-derived factor (PEDF, also known as SerpinF1). In one embodiment, the inhibitors are antibodies against BMP-4 and PEDF, respectively. The medium allows to culture keratinocytes under... Agent: Birch Stewart Kolasch & Birch

20090280093 - Compositions and populations of cells obtained from the umbilical cord and methods of producing the same: The present invention relates to populations and compositions of stem and progenitor cells derived from the umbilical cord, and methods of obtaining the same. In some embodiments, one or more entire umbilical cords or sections thereof are subjected to a process where a cell population is derived without prior removal... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20090280092 - G-protein coupled receptor 83 as a molecular switch for the induction of regulatory (immunosuppressive) t-cells: The present invention makes use of the role of the G-protein coupled receptor 83 (GPCR83) in the induction of regulatory T cells (Tregs) during the course of ongoing immune response. The present invention relates to means and methods for identifying compounds that are interacting with the GPCR83 polypeptide, and to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090280096 - Pancreatic endocrine progenitor cells derived from pluripotent stem cells: The invention provides pluripotent cells modified to overexpress Pdx1 and Ngn3. Pluripotent cells include embryonic stem cells and induced pluripotent stem cells. Methods of producing pancreatic endocrine progenitor cells from ES cells or from iPS cells by forced expression of Pdx1 and Ngn3 are provided. Pancreatic endocrine progenitor cells are... Agent: Morrison & Foerster LLP

20090280097 - Pluripotent cells: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells... Agent: Karen S. Canady Canady & Lortz LLP

20090280094 - Treatment of ischemic diseases using erythropoietin: (c) administering the collected peripheral blood mononuclear cells to a target site of the subject. Peripheral blood mononuclear cells, and particularly CD34-positive cells, are mobilized into the peripheral blood of a subject by the administration of erythropoietin to the subject. The method of the present invention is useful for the... Agent: Fish & Richardson PC

20090280102 - Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof: Methods and compositions are provided for inhibiting the growth of susceptible microorganisms by contacting the microorganisms, in the presence of a peroxide and chloride or bromide, with myeloperoxidase and at least two activity enhancing agent amino acids.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090280101 - Method for conversion of uric acid to allantoin and related enzymes: It is described a polypeptide molecule able to selectively modulate uric acid conversion into S(+)-allantoin. A pharmaceutical composition for treating uric acid related disorders and a process to selectively modulate uric acid conversion into S(+)-allantoin are also disclosed.... Agent: Juneau Partners

20090280100 - Preventive or therapeutic agent for inflammatory ocular-surface diseases:

20090280104 - Compositions and methods for inhibiting shiga toxin and shiga-like toxin: The present invention provides compositions and methods for treating or preventing infection by shiga toxin producing bacteria.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090280103 - Regulation of muscle repair: Biochemical signals originating at sites of focal adhesions between muscle fibers are functionally involved in the mechano-dependent governance of muscle gene expression. Herein included information describes a methodology to promote improvements of motor function by combining contraction-related and pharmacological interventions which stimulate focal adhesion signaling and a diagnostic use to... Agent: Grant Anderson LLP C/o Portfolioip

20090280105 - Novel fungal enzymes: This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method... Agent: Sheridan Ross PC

20090280106 - Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use: This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for... Agent: Barbara A. Shimei Director, Patents & Licensing

20090280107 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20090280110 - Cell model for alzheimer's disease pathology: The present invention encompasses compositions and methods for studying in cell culture the pathologic changes associated with Alzheimer's disease. The present invention further relates to methods for studying and detecting early events in the conversion of healthy neurons to Alzheimer's disease neurons.... Agent: University Of Virginia Patent Foundation

20090280109 - Ilt3 and ilt4-related compositions and methods: This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28− cell and a vitamin D3 analog. This invention also provides methods for generating a tolerogenic antigen-presenting cell, and increasing the expression of ILT3 and/or ILT4 by an antigen-presenting cell. This invention further provides methods... Agent: Ropes & Gray LLP

20090280112 - Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells: Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor.... Agent: Bozicevic, Field & Francis LLP

20090280111 - Isolation of the mitotic spindle matrix and its methods of use: The invention encompasses a purified preparation of the mitotic spindle matrix essential for mitotic spindle assembly, which allows for identifying an agent that modulates a cell division and/or differentiation signaling pathway comprising determining the effect of the agent on spindle formation, MT nucleation, or lamin matrix assembly wherein the change... Agent: Morgan Lewis & Bockius LLP

20090280114 - Prevention of brain inflammation as a result of induced autoimmune response: A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090280108 - Serum amyloid a protein in inflammation and obesity: The present invention relates to the discovery that acute-phase serum amyloid protein A (A-SAA) is a biomarker for obesity and certain abnormal conditions. The present invention, therefore, provides methods of diagnosing obesity or an abnormal condition in a subject The present invention also provides methods of monitoring the progression of... Agent: Merchant & Gould PC

20090280113 - Target for regulating multiple sclerosis: Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090280115 - Dihydropteridinones in the treatment of respiratory diseases: t

20090280116 - Humanized antibodies against tl1a: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.... Agent: Foley And Lardner LLP Suite 500

20090280118 - Methods and compositions for treating and preventing disease associated with alphavbeta5 integrin: The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin.... Agent: Townsend And Townsend And Crew, LLP

20090280117 - Methods for the treatment or prevention of immune disorders using anti-cd40 antibodies: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.... Agent: Townsend And Townsend And Crew LLP

20090280119 - Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090280121 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells: The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne... Agent: Zymogenetics, Inc. Intellectual Property Department

20090280120 - Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies,... Agent: Proskauer Rose LLP

20090280122 - Use of a virus regimen for the treatment of diseases: The use of a virus regimen, especially an oncolytic regimen for the production of a medicament for the treatment of a disease, especially cancer is described. The virus regimen is applied after reducing, shutting down or modifying functioning of the immune system in a controlled manner. In a preferred embodiment... Agent: Millen, White, Zelano & Branigan, P.C.

20090280123 - Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same: An isolated polynucleotide comprising a nucleic acid sequence encoding a KIF18A polypeptide being expressed in mesenchymal stem cells is disclosed. Methods of detecting same are disclosed as well as methods of using same for modulating estrogen signaling in cells.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090280124 - Methods for the diagnosis and treatment of preeclampsia: Provided by the present invention are methods for treating and diagnosing preeclampsia, as well as kits for use in diagnosing patients with a higher risk of preeclampsia.... Agent: Marshall, Gerstein & Borun LLP

20090280127 - Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-i: The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.... Agent: Myers Bigel Sibley & Sajovec

20090280126 - Peptide-based immunization therapy for treatment of atherosclerosis: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090280125 - Prion epitopes and methods of use thereof: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.... Agent: Robins & Pasternak

20090280128 - Anti-ilt7 antibody: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of... Agent: Medimmune, LLC Patrick Scott Alban

20090280129 - High concentration antibody and protein formulations: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders... Agent: Morrison & Foerster LLP

20090280130 - Method for the treatment of anthrax toxicity: Bacillus anthracis is a spore-forming Gram positive bacterium that is the causative agent of anthrax infection. Vascular leakage and pleural effusions are hallmarks of the fulminant phase of human anthrax disease following infection. The present invention provides a method of halting, treating, and preventing the rapid toxic effects of human... Agent: David S. Resnick

20090280131 - Il-17 antagonistic antibodies: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g.... Agent: Novartis Corporate Intellectual Property

20090280132 - Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor agonist... Agent: Multicell Technologies, Inc. C/o David Lewis

20090280133 - Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof: Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20090280134 - Compositions and methods for inhibiting toxin a from clostridium difficile: The present invention provides compositions and methods for treating or preventing infection by Toxin A producing bacteria.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090280136 - Immunization of fish with plant-expressed recombinant proteins: Plants are produced that express an amino acid sequence that, when administered to a fish, produce an antigenic or immune response in the fish. The amino acid sequence in one embodiment is an antigen from an organism that causes pathology in fish. The plant tissue may be fed to the... Agent: Patricia A. Sweeney

20090280137 - Methods, compositions, and sequences of zp-binding peptides for immunocontraception of dogs and other animals: Disclosed are methods, compositions, and zona pellucida binding peptides and polypeptides for use in immunocontraception of canines and other animals. The disclosed compositions may include pharmaceutical compositions.... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090280135 - Recombinant mhc molecules useful for manipulation of antigen-specific t-cells: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and... Agent: Black Lowe & Graham PLLC

20090280138 - Peptide: The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their use in diagnosis and therapy of cancer.... Agent: Townsend And Townsend And Crew, LLP

20090280139 - Novel norovirus particle for use as an antiviral or vaccine: Norovirus capsid protein monomers having only the P domain, and not the hinge or S domain, can assemble spontaneously into an icosahedral form herein called the P-particle. Factors affecting the formation and stability of the P-particle, as well as providing methods for diagnosing and treating Norovirus-infected individuals and creating a... Agent: Hasse & Nesbitt LLC

20090280140 - Early detection of mycobacterial disease using peptides: A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090280141 - Streptococcal genes: Peptides derived from S. pneumoniae are identified as virulence determinants and may be useful in the preparation of vaccines for the treatment of infection. The peptides may be used as antigens or in the preparation of attenuated microorganisms for use as live oral vaccines.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090280143 - Genetic adjuvants for immunotherapy: The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions... Agent: Glenn P. Ladwig Saliwanchik, Lloyd & Saliwanchik

20090280142 - Methods of diagnosis and treatment of osteoporosis: b) measuring the concentration of at least a marker which is either bacteria, bacteria produced factors, or HSPs. The method may further include comparing the concentration with concentrations from the same individual over a period of time or against a standard concentration. The marker may be a bacteria, a chaperone... Agent: Nutter Mcclennen & Fish LLP

20090280144 - Recombinant newcastle disease virus rna expression systems and vaccines: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral... Agent: Ropes & Gray LLP

20090280145 - Adjuvant viral particle: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein... Agent: Patterson & Sheridan, L.L.P.

20090280146 - Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria: This invention relates to the use of a preparation of killed or non infectious Gram positive bacteria such as Gram positive facultative intracellular bacteria, for example mycobacteria, for the treatment of intestinal inflammatory syndromes such as Crohn's disease or ulcerative colitis.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090280148 - Casein nanoparticle: i

20090280147 - Compositions comprising dye-loaded particles:

20090280149 - Cosmetic and method for production thereof: A cosmetic in an emulsified state, in which a titanium dioxide microparticle coated with hydrous silicic acid and/or a hydrous silicate compound, a higher alcohol, an oily component other than the higher alcohol, and a polysaccharide are contained, and the polysaccharide containing at least one of fucose, glucose, glucuronic acid... Agent: Mcginn Intellectual Property Law Group, PLLC

20090280150 - Targeted and individualized cosmetic delivery: A system and methods are provided for targeted and individualized delivery of multiple skin benefit agents to the skin of a user. The image of a predetermined treatment area of the user's skin is first captured by an imaging device. The captured image data is then analyzed by a computing... Agent: The Estee Lauder Cos, Inc

20090280151 - Fabric with active principles and relevant recharging method of the active principles: The fabric consists of lycra fibres and microfibres and it has long the fibres a glycoprotein (9) and an exapeptide (10). The woof of this fabric and the active principles given to these two substances (9, 10) prevent and/or give the first cures to the diabetic foot.... Agent: Pearne & Gordon LLP

20090280154 - Biodegradable scaffold with ecm material: We add discontinuous regions of Extra Cellular Matrix (ECM) to a biodegradable scaffold. Hereby it is possible to combine the range of physical properties the scaffold can offer with the reconstructive properties of the ECM. The optimal amount of discrete ECM material for each application is disclosed and this concentration... Agent: Jacobson Holman PLLC

20090280156 - Bioimplant: To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 90% or less is formed at a predetermined area of the bioimplant and an... Agent: Birch Stewart Kolasch & Birch

20090280155 - Coating systems for the controlled delivery of hydrophilic bioactive agents: Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The... Agent: Kagan Binder, PLLC

20090280153 - Electrical devices, anti-scarring agents, and therapeutic compositions: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.... Agent: Seed Intellectual Property Law Group PLLC

20090280152 - Tropoelastin for promoting endothelial cell adhesion or migration: The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.... Agent: Kelley Drye & Warren LLP

20090280157 - Method of modifying materials surfaces: The present invention relates to “grafting to” methods of modifying materials surfaces with high-density polymer brushes. A method of the present invention comprises contacting in succession or simultaneously an activated material surface, a solution of a polymeric material having a polymeric backbone with pendant reactive moieties, and a melt of... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090280158 - Sustained release delivery of active agents to treat glaucoma and ocular hypertension: The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or... Agent: Schwegman, Lundberg & Woessner, P.A.

20090280159 - Process for manufacturing chewable dosage forms for drug delivery and products thereof: A palatable, soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the soft chews... Agent: Dla Piper LLP (us)

20090280160 - Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption: Pharmaceutical compositions comprising phenylephrine or a pharmaceutically acceptable salt thereof and methods for administering the pharmaceutical compositions wherein the composition is formulated for systemic absorption of phenylephrine that avoids first pass metabolism. The compositions of the invention are formulated to be applied to oral mucosa of an animal to allow... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090280161 - Thin film multilocular structure made of collagen, member for tissue regeneration containing the same, and method for producing the same: The present invention provides a new structure made of collagen for improving promotion of nerve tissue regeneration, curing and regeneration of a defective part of a soft biological tissue and so on without using laminin or nerve growth factor (NGF), and a member for tissue regeneration including the same. The... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090280162 - Layered wound dressing: A wound dressing including at least one biocompatible support material and at least one polysaccharide as a hemostatic means (hemostyptic) and/or that unites severed regions of body tissue, and having a layered structure of at least one layer of the support material and at least one layer of the polysaccharide.... Agent: Ip Group Of Dla Piper LLP (us)

20090280168 - Chlamydia omp antigen: The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polypeptides relate to the 98 KDa OMP antigen designated CPN100686 RY 54 (SEQ ID No:14, encoded in... Agent: Smart & Biggar P.o. Box 2999, Station D

20090280165 - Compounds that bind alpha5beta1 integrin and methods of use: The present invention provides biologically active compounds that bind an αsβi integrin. Also included in the present invention are methods for using such biologically active compounds.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090280167 - Enhancement of drug therapy by mirna: This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for... Agent: Leydig Voit & Mayer, Ltd

20090280166 - Ferritin as a therapeutic target in abnormal cells: Compositions for treatment of iron related diseases comprise an inhibitor of ferritin. An inhibitor of ferritin is active to reduce the level of H ferritin protein in a cell and/or to reduce the activity of H ferritin in a cell. Compositions providing cytoprotection, regulation of iron, increasing longevity and viability... Agent: J. Rodman Steele Novak Druce & Quigg LLP

20090280163 - High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them: The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetic agents to cells and tissues.... Agent: Proskauer Rose LLP

20090280164 - Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes: A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic... Agent: Foley & Lardner LLP

20090280170 - Compositions of gnrh related compounds and processes of preparation: The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound,... Agent: Myers Bigel Sibley & Sajovec

20090280169 - Compositions of peptides and processes of preparation thereof: The present invention provides composition of comprising a therapeutically effective amount of at least one peptide, polypeptide, analog or derivative thereof and a sufficient amount of at least one stabilizing agent to improve the stability of the peptide, polypeptide, an analog or derivative thereof, wherein at least one stabilizing agent... Agent: Myers Bigel Sibley & Sajovec

20090280171 - Method of treatment with predictably breakable pharmaceutical tablets: The invention involves the use of finished dosage forms, e.g., tablets, by breaking or otherwise dividing them to produce a predictably accurate smaller or lower dose.... Agent: Accu-break Technologies, Inc.

20090280172 - Galenic formulations of organic compounds: The present invention relates to a dosage form for transmucosal administration comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and an excipient for transmucosal delivery, wherein the active ingredient is present in an amount of 0.001 to 80% by weight based on the total weight... Agent: Novartis Corporate Intellectual Property

20090280173 - Multilayer omeprazole tablets: Multilayer tablets of Omeprazole and/or a salt thereof essentially bioequivalent in terms of plasma Omeprazole Cmax and AUC to Omeprazole capsules and/or Omeprazole Magnesium tablets consisting of multiple unit pellets are provided. Also provided are methods for production of these multilayer tablets and methods for their use in treating dyspepsia,... Agent: Licata & Tyrrell P.C.

20090280176 - Controlled release formulations of alprazolam: A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided.... Agent: Foley And Lardner LLP Suite 500

20090280175 - Multilayer proton pump inhibitor tablets: Multilayer tablets of a proton pump inhibitor essentially bioequivalent in terms of plasma Cmax and AUC to capsules and/or tablets consisting of multiple unit pellets of the proton pump inhibitor are provided. Also provided are methods for production of these multilayer tablets and methods for their use in treating dyspepsia,... Agent: Licata & Tyrrell P.C.

20090280174 - Solid pharmaceutical preparation: It is intended to provide a long-acting solid pharmaceutical preparation which has an immediate release part and a sustained release part containing tramadol or a pharmaceutically acceptable salt thereof, is fast-acting and stably has an excellent release property showing little pH dependency in the initial elution. The invention relates to... Agent: Oliff & Berridge, PLC

20090280177 - Pharmaceutical preparation for treating fibromyalgia: It is difficult to develop pharmaceutical agents for treating fibromyalgia since both the pathogenetic cause and the onset mechanism remain to be clarified. An antirheumatic agent salazosulfapyridine was administered to fibromyalgia patients. Unexpectedly, salazosulfapyridine was seen to be effective in fibromyalgia patients in whom neither the rheumatoid factor nor an... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090280178 - Process for the preparation of sevelamer hydrochloride and formulation thereof: Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation.... Agent: Pharmaceutical Patent Attorneys, LLC

20090280180 - Collagen-based matrices with stem cells: Collagen based-matrices and methods of their use are described. More particularly, collagen-based matrices for differentiating stem cells and progenitor cells, and for producing and isolating blood vessels and vascularized graft constructs are described.... Agent: Barnes & Thornburg LLP

20090280181 - Delivery of nucleic acid complexes from particles: Embodiments of the invention include particles with nucleic acid complexes, medical devices including the same and related methods. In an embodiment, the invention can include a method of making a medical device. The method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, adsorbing the... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090280179 - Resorbable calcium phosphate based biopolymer-cross-linked bone replacement material: A resorbable bone replacement material made of calcium phosphate particles of different phases which are embedded in an inventive-specific cross-linked collagen matrix. The goal is to form a non-brittle, bone replacement moulded body having a positive fit, i.e. having a shape which is anatomic and/or corresponds to the defect, which... Agent: Jordan And Hamburg LLP

20090280182 - Devices for the treatment of wounds and methods and kits therefor: Interpenetrating network hydrogels are described that may be incorporated into wound dressings and/or in implants. The properties of the interpenetrating network hydrogel may be tuned to control an amount of moisture in a wound environment. The devices, methods, and kits described herein may be adapted to treat a variety of... Agent: Lumen Patent Firm

20090280183 - Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration: The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090280185 - Particulate wood preservative and method for producing the same: A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090280184 - Pharmaceutical composition, method of preparation and methods of treating aches/pains: Provided are methods and compositions useful for treating/aches and/or pains. The compositions comprise an herbal therapeutic agent and an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20090280186 - Process for producing spherical base granule comprising easily water-soluble drug: Provided is a process for producing spherical base granules comprising a easily water-soluble drug and suited for film coating by spraying a layering liquid over pharmaceutically inert spherical core particles, thereby coating the particles with a layer comprising the easily water-soluble drug, wherein (1) the spherical core particles have a... Agent: Staas & Halsey LLP

20090280188 - Asymmetric functionalizated nanoparticles and methods of use: Disclosed herein are asymmetrically functionalized nanoparticles. Further disclosed herein are methods of preparing asymmetrically functionalized nanoparticles. Asymmetrically functionalized nanoparticles can be used in various therapeutic methods.... Agent: Marshall, Gerstein & Borun LLP

20090280187 - Oxidation-stable granulate containing unsaturated fatty acids: One aspect of the invention relates to a water-dispersible granulate having a mass weighted average diameter of at least 100 m, said granulate comprising: 40-90 wt. % of carbohydrates; 2-30 wt. % of lipids containing at least 1% unsaturated fatty acids by weight of the granulate and at least 30... Agent: Unilever Patent Group

20090280189 - System for the liberation of an active principle and its use: A local system for the liberation of an active principle is described which consists of spherical bodies which are composed of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate and, if necessary, zirconium dioxide and/or barium sulphate and a pharmaceutical active principle, which contains at least one hemostyptically effective compound stable... Agent: Norris, Mclaughlin & Marcus, Pa

20090280190 - Anti-angiogenic peptides from the n-terminus of endostatin: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090280191 - Preventive remedial therapeutic agent for phosphorus impairment, oral agent for adsorbing phosphate ion contained in food, beverage and chemical, and process for producing them: The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present.... Agent: Osha Liang L.L.P.

20090280192 - Method for treating or preventing alzheimer's disease: Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of an agent which reduces serum insulin levels.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090280193 - Enerceutical mediated activation of the alternative cellular energy (ace) pathway in the therapy of diseases: Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or... Agent: William John Martin

20090280194 - Use of nitroxyl (hno) for the treatment of cancers overexpressing mat-8: Compositions and methods for treating hormone dependent or independent cancers overexpressing MAT-8 in a patient by administration of nitroxyl-donating compounds and treating patient suffering from cancers such as prostate cancer, breast cancer, pancreatic cancer, colon cancer and lung cancer.... Agent: Foley & Lardner LLP

20090280197 - Cell activator, collagen production promoter, skin whitening agent, antioxidant agent, antiinflammatory agent, aromatase activity promoter, protease activity promoter, external preparation for skin, and food: The present invention provides a cell activation agent, a collagen production accelerator, a whitening agent, an antioxidant, an anti-inflammatory agent, an aromatase activity accelerator, a protease activity accelerator, a skin external preparation, and food, which all contain an extract of Hibiscus makinoi.... Agent: Squire, Sanders & Dempsey L.L.P.

20090280196 - Cissus quadrangularis plant extracts for treating osteoporosis and the extraction process thereof: The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of Cissus quadrangularis plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is... Agent: Pearl Cohen Zedek Latzer, LLP

20090280195 - Methods for the treatment of addictive disease and addiction to chemical substances and addictive behaviors using a formula containing the following formulation: mucuna pruiens, n acetyl l cysteine, magnesium citrate: The invention is directed at the formulation of Mucuna pruiens, N Acetyl L Cysteine and Magnesium Citrate. This formulation augments dopamine in the striatal area of the human brain and stabilizes membranes by restoring normal neurotransmitter levels and decreasing endogenous catecholamines. These effects are beneficial in the short and long... Agent: Thomas Eugene Hoshour

20090280198 - Combined effects of nutrients on proliferation of stem cells: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or... Agent: Bryan Cave LLP

20090280199 - Neuroprotective compositions and methods of using same: The present invention provides compositions and methods for preconditioning, providing neuroprotection to, and/or enhancing the neural recovery of an individual. The compositions include pomegranate extract, blueberry extract, curcumin and/or magnesium citrate, and Omega 3 fatty acids. The compositions can be used in beverages or food products. In preferred embodiments, the... Agent: Morgan, Lewis & Bockius LLP (sf)

20090280200 - Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors: An herbal extract which induces immune cells to produce interferon and activates Toll-like receptors and a preparation method thereof are provided. The herbal extract is extracted from an effective amount of raw material including Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix. Glycyrrhizae Radix, Bupleuri Radix,... Agent: Lowe Hauptman Ham & Berner, LLP

20090280201 - Natural extract for the control of botrytis cinerea at pre- and post-harvest: Obtaining, producing and using metabolites having anti-botrytis cinerea properties from a natural extract of a native Chilean plant. An in vitro cultivated quillay extract (Quillaza saponaria Mol.), which allows improving the antifungal activity as the result of the enrichment of some secondary metabolites not found in the in vivo plants.... Agent: Hasse & Nesbitt LLC

20090280203 - Compositions of atomized or lyophilized maca (lepidium meyenii) extracts and atomized or lyophilized yacon (smallanthus sanchifolius) extracts as adjuvants in the treatment of different conditions: The present invention refers to compositions of atomized or lyophilized extracts of selected maca hypocotyls of the red and black variety and atomized or lyophilized parts of the yacon plant selected from leaves and roots. The invention also refers to the methods to prepare such compositions using aqueous or hydroalcoholic... Agent: John Alexander Galbreath

20090280202 - Extracts of aristolochia longa pomer and uses thereof: Methods of extracting from a part of a variety of the species Aristolochia Longa pomer a biologically active extract are disclosed. Methods of reducing cell growth in a subject and inducing apoptosis in a cell are also disclosed.... Agent: Traskbritt, P.C.

20090280204 - Use of extracts of capraria biflora in the prevention and/or treatment of senile cataracts: The invention provides methods for treating and/or preventing the recurrence of a senile cataract, and/or for inhibiting the development of a senile cataract and/or an incipient senile cataract, in a human or animal subject. The invention further provides nutraceutical compositions suited for the same, derived from an extract of the... Agent: Gottlieb Rackman & Reisman PC

20090274620 - Hybridoma cell line g250 and its use for producing monoclonal antibodies: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090274618 - Tadg-15: an extracellular serine protease overexpressed in carcinomas: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present... Agent: Benjamin Aaron Adler, Ph.d., J.d. Adler & Associates

20090274619 - Tumor vasculature markers and methods of use therof: This invention provides methods of detecting and localizing tumor vasculature cells (TVC) and solid tumors; and treating, impeding vascularization of, and determining the stage of solid tumors in a subject, comprising the step of contacting a subject or a TVC with a ligand that binds to a nucleic acid molecule... Agent: Pearl Cohen Zedek Latzer, LLP

20090274622 - Necrosis avid tracer agent: The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as... Agent: Clark & Elbing LLP

20090274621 - Use of pyrene to carry non-peptide agents across the blood brain barrier: Described are methods for delivering a non-peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a non-peptide agent and (ii) pyrene, and related detection and therapeutic method.... Agent: Foley And Lardner LLP Suite 500

20090274623 - In vivo imaging agents for met receptor tyrosine kinase: Provided are in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof, coupled to a signal generator, and the mutein coupled to a signal generator is disposed in a pharmaceutically acceptable carrier. Also provided are diagnostic methods using in vivo imaging agents... Agent: General Electric Company Global Research

20090274624 - Radiotracers for imaging p-glycoprotein function: P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established or prospective chemotherapeutics (a phenomenon known as multidrug resistance). This invention concerns... Agent: Townsend And Townsend And Crew, LLP

20090274625 - Compositions and methods for the treatment of cancer: The instant invention provides methods and compositions for the treatment and diagnosis of cancer, e.g., cancers characterized by the expression of prostate specific membrane antigen (PSMA).... Agent: Edwards Angell Palmer & Dodge LLP

20090274627 - Composition for regeneration of periodontal soft tissue and method for producing the same: It is intended to provide a composition for regeneration of periodontal soft tissue less invasively and a method for producing the composition. The composition for regeneration of periodontal soft tissue is prepared so as to contain a cell selected from an undifferentiated/stem cell or a blast cell having an ability... Agent: Oliff & Berridge, PLC

20090274626 - Targeting tnf-alpha converting enzyme(tace)- dependent growth factor shedding in cancer therapy: The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods... Agent: Lawrence Berkeley National Laboratory

20090274630 - Red blood cell-derived vesicles as a nanoparticle drug delivery system: Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The... Agent: Ipc Intellectual Property Connections, Inc.

20090274628 - Reconstitutable microsphere compositions useful as ultrasonic contrast agents: Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous... Agent: Medlen & Carroll, LLP

20090274629 - Sanitizing composition and method of preparation: The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwash composition comprising alcohol, water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are... Agent: Booth Udall, PLC

20090274631 - Rnai-mediated inhibition of histamine receptor h1-related conditions: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.... Agent: Alcon

20090274632 - Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof... Agent: Hunton & Williams LLP Intellectual Property Department

20090274634 - Novel crosslinked polymeric substrates methods of preparation and end use applications of the substrates: e

20090274633 - Tooth powder containing elvan as radiation source of far infrared ray: The present invention relates to tooth powder containing elvan as a radiation source of a far infrared ray wherein the tooth powder includes 10 weight % to 90 weight % of elvan as a radiation source of a far infrared ray and 10 weight % to 90 weight % of... Agent: Merchant & Gould PC

20090274635 - bactericide having selectivity to cariogenic bacterium, and a method for sterilization of cariogenic bacterium: The bacteriolytic effect of a bacterial cell wall lytic enzyme can be increased by the addition of a surfactant to the enzyme. As a result, the time required for lysis of cariogenic bacterium with the bacterial cell wall lytic enzyme can be shortened, and the practical utility of the bacterial... Agent: Oliff & Berridge, PLC

20090274636 - Tooth enamel dissolution inhibitor: e

20090274638 - Cosmetic use of a c-glycoside derivative in combination with ascorbic acid: The present invention relates to a cosmetic use of a synergistic combination of at least one C-glycoside derivative with at least ascorbic acid, or one of its derivatives or analogs, for preventively or curatively treating the signs of aging of body or facial skin, irrespective of whether they are chronobiological... Agent: Oliff & Berridge, PLC

20090274637 - Depigmenting or brigthening cosmetic composition at least one oxazolin as an active ingredient: The invention relates to the cosmetic use of at least one oxazolin as a depigmenting active ingredient in a depigmenting composition, and to the associated cosmetic treatment method. The invention also relates to the use of at least one oxazolin for preparing an active medicament as a depigmenting agent, and... Agent: Birch Stewart Kolasch & Birch

20090274639 - Composition for hair: It is an object of the present invention to provide a composition for hair which comprises a hydrophobic ingredient although it has an extremely low alcohol concentration, and which has a low viscosity. The present invention provides a composition for hair having a viscosity of 30 P or less, which... Agent: Sughrue Mion, PLLC

20090274640 - Hair care compositions: Hair care compositions are disclosed which comprise a silicone polyurethane polymer, an ester, and a fluorosilicone. The compositions are useful for improving color retention of artificially colored hair.... Agent: Avon Products, Inc.

20090274641 - Cosmetic composition comprising one or more vinylformamide/vinylformamine copolymers and one or more thickening polymers: i

20090274642 - Hair care compositions for preventing oxidative damage to hair, methods of use, and methods of marketing such compositions: Hair care compositions, methods, and methods of marketing that can prevent oxidative damage to hair. Such compositions comprise a follicular fungi reduction agent (“FFRA”) and can be applied to any areas where the appearance of less oxidative damage is desired, such as the scalp or face. The present invention also... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090274643 - Low viscosity, high molecular weight linear random-block silicone polyalkyleneoxide copolymers: The present invention describes novel non-hydrolyzable, linear, random block copolymers comprising units of polysiloxanes and polyalkyleneoxides linked by bis-aminofunctional groups. These copolymers have been successfully applied as textile enhancers as well as conditioning agents for hair and skin care products.... Agent: Momentive Performance Materials Inc. C/o Dilworth & Barrese, LLP

20090274644 - Ant eradication composition and method: A composition and method for eradicating ants is provided wherein the composition includes borax, sugar and yeast. The messenger ants taste the composition; the workers take the composition back to the Queen who also eats the composition. The composition renders her infertile, and later distends the gastrointestinal tract.... Agent: Robert M. Schwartz, P.A.

20090274645 - Gall midge pheromone mixture: The present invention relates to a pheromone composition for attracting male Hessian fly, Mayetiola destructor (Say), for monitoring and/or combating purpose, said composition consisting of (2S,10E)-I-O-tridecen-2-yl acetate(2S-E10-13:OAc), (2S)-tridecan-2-yl acetate(2S-13:OAc), (2S,10E)-10-tridecen-2-ol (2S-E10-130H), and optionally (2S,8E,10E)-8,10-tridecadien-2-yl acetate(2S-E8-E10-13:OAc) and/or (2S,8Z,10E)-8,10-tridecadien-2-yl acetate(2S-Z8-E10-13:OAz), as well as a method for attracting said Hessian fly using such... Agent: Gauthier & Connors, LLP

20090274646 - Methods for controlling molluscs: Novel materials for controlling molluscs, such as snails and slugs, using carbohydrates including celluloses, hemicellulose complexes, and/or lignin, for inducing death in molluscs. The materials are non-toxic, will not contaminate a drinking water supply, will not harm fish, birds or wild life, will not cause any harmful effects if swallowed... Agent: Mark D Miller Kimble, Macmichael & Upton

20090274649 - Bispecific antibody point mutations for enhancing rate of clearance: A mutant bispecific antibody that includes (a) a human hinge constant region from IgG having one or more amino acid mutations in the CH2 domain, (b) two scFvs; and (c) two Fvs has been constructed. This type of antibody displays enhanced clearance, which has been found to be particularly useful... Agent: Immunomedics, Inc.

20090274648 - Hepatitis c virus inhibitors: m

20090274652 - Hepatitis c virus inhibitors:

20090274647 - Immunotherapeutic formulations with interleukin-2-neutralizing capacity:

20090274650 - Inhibitors of aspartyl protease: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and... Agent: Ropes & Gray LLP

20090274653 - Interleukin-2 mutants with reduced toxicity: Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a... Agent: Foley & Lardner LLP

20090274651 - Therapeutic agent for infections, and treatment method using the same: The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo... Agent: Curtis L. Harrington

20090274655 - 2-carboxy thiophene derivatives as anti viral agents: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090274654 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: Nutter Mcclennen & Fish LLP

20090274656 - Hepatitis c virus inhibitors: e

20090274657 - Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090274658 - Tight junction modulating peptides for enhanced mucosal delivery of therapeutic compounds: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a... Agent: Woodcock Washburn LLP

20090274659 - Compositions and methods for producing fermentation products and residuals: The present invention provides compositions and methods designed to increase value output of a fermentation reaction. In particular, the present invention provides a business method of increasing value output of a fermentation plant. The present invention also provides a modified fermentation residual of higher commercial value. Also provided in the... Agent: Wilson, Sonsini, Goodrich & Rosati

20090274669 - Dendritic cells transiently transfected with a membrane homing polypeptide and their use: The invention provides improved methods of producing dendritic cells (“DCs”) that transiently express a membrane homing peptide and optionally at least one additional antigen. These DCs have the ability to home to lymph nodes in vivo. In some embodiments, these DCs can be administered to a patient intravenously and can... Agent: Merix Bioscience, Inc.

20090274670 - Dph2 gene deletion mutant and uses thereof: Diphtheria and Pseudomonas infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death. Diphthamide formation on EF-2 is a prerequisite step in the inactivation of EF-2, and Dph proteins have... Agent: Ogilvy Renault LLP

20090274671 - Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies: Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes... Agent: Edwards Angell Palmer & Dodge, LLP

20090274660 - Pluripotent therapeutic compositions and uses thereof: Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090274662 - Methods and kits for the treatment of inflammatory bowel disorder conditions: The present invention comprises methods and kits that are useful for the treatment an inflammatory bowel disease. The methods comprise administering to a mammal in need of treatment a composition comprising an active agent in combination with a probiotic and/or optionally an antibiotic.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090274661 - Use of bifidobacterium longum for the prevention and treatment of inflammation: The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of bifidobacterium longum ATCC BAA-999.... Agent: K&l Gates LLP

20090274672 - Lactobacillus isolates having anti-inflammatory activities and uses of the same: Disclosed herein are two Lactobacillus isolates having anti-inflammatory activities and beneficial probiotic properties, i.e., Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and... Agent: Sunstein Kann Murphy & Timbers LLP

20090274673 - Composition for topical treatment of acne: The composition described is to be applied topically to the skin to treat acne and other skin disorders caused in part or wholly by bacterial or mycosal infections. Acne and related skin disorders have complex causes. This formula contains compounds, including an effective amount Bacillus amyloliquefaciens (Bam), that have distinct... Agent: James C. Eaves Jr. Greenebaum Doll & Mcdonald PLLC

20090274666 - B7-h1, a novel immunoregulatory molecule: The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Millen, White, Zelano & Branigan, P.C.

20090274668 - Combined regulation of neural cell production: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing... Agent: Fish & Richardson P.C.

20090274663 - Materials and methods relating to cell based therapies: The invention provides a novel multipotent cell population of adult origin that can be used to treat ageing and disease, particularly by transplantation to site of cellular damage.... Agent: Morgan Lewis & Bockius LLP

20090274664 - Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture: There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090274667 - Retinal pigment epithelial stem cells: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention... Agent: Darby & Darby P.C.

20090274665 - Stem cells for treating lung diseases: The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow.... Agent: Sheridan Ross PC

20090274677 - Antioxidant for use in cosmetic, medicated and pharmaceutical preparations: The invention provides the use a 2,2-dimethyl chroman as a SOD mimetic in a cosmetic preparation. Cosmetic preparations comprising a 2,2-dimethyl chroman as a SOD mimetic are described, as well as methods for treating or preventing free radical damage to skin cells and treating or preventing hair loss which comprise... Agent: Bozicevic, Field & Francis LLP

20090274676 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and... Agent: Wilson, Sonsini, Goodrich & Rosati

20090274674 - Heterocyclic oxime compounds, process for their preparation and pharmaceutical compositions containing them: p

20090274675 - Migraine tonic: This invention is proposing a combination of a system of migraine headache remedies from non-prescription pharmaceuticals in the form of an aqueous drinkable tonic utilizing as the component foundation the main ingredient Ubiquinone (Co-enzyme-Q10) coupled with one or more of the following non-prescription natural or synthesized pharmaceuticals to include but... Agent: Govindan Gopinathan, M.d.

20090274678 - Compositions and methods to treat urinary incontinence: A method is disclosed for treatment of urinary incontinence. The method includes the steps of providing to a person or animal, in the vicinity of a pubo-urethral ligament of the person or animal, a composition including collagen macromolecules that have hydroxyphenyl side groups substituted thereon, which are reacted to form... Agent: Pearne & Gordon LLP

20090274680 - Human phospholipases: The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.... Agent: Foley And Lardner LLP Suite 500

20090274681 - Novel gene encoding a dna repair enzyme and methods of use thereof: An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA,... Agent: Dann, Dorfman, Herrell & Skillman

20090274679 - Production and use of human butyrylcholinesterase: The present invention concerns the production of human butyrylcholinesterase (BuChE) in transgenic plants and use of the derived BuChE as effective countermeasures against toxic agents such as pesticides, toxins, certain drugs and non-conventional warfare agents, as well as treatments for diseases and conditions associated with depressed cholinesterase levels.... Agent: Fulbright & Jaworski L.L.P.

20090274682 - Demethylation and inactivation of protein phosphatase 2a: Embodiments of the present invention relate to atomic coordinates for PME-1 alone or in complex with PP2A, as well as methods for using these atomic coordinates to prepare inhibitors of PME-1 and/or PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PME-1... Agent: Pepper Hamilton LLP

20090274683 - Adamts13 genes and proteins and variants, and therapeutic compositions and methods of utilizing the same: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments,... Agent: Casimir Jones, S.c.

20090274687 - Attenuation of hypoxia induced cardiovascular disorders: Blockade of stromal derived factor-1 (SDF-1), a stem cell mobilizer and/or its receptor, chemokine receptor 4 (CXCR4) attenuates and reverses hypoxia-induced cardiopulmonary remodeling in vivo. Compositions for treating hypoxia-induced cardiovascular disorders modulate the SDF-1/CXCR4 axis.... Agent: Darby & Darby P.C.

20090274685 - Ilt3 polypeptides and uses thereof: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection... Agent: Ropes & Gray LLP

20090274684 - Methods for the identification of modulators of osgpr114 or osgpr78 activity, and their use in the treatment of disease: This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR 114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical agents identified by these methods.... Agent: Osi Pharmaceuticals, Inc.

20090274686 - Nucleoside phosphonate derivatives: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also... Agent: Elmore Patent Law Group, PC

20090274688 - Antibodies to opgl: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090274692 - Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related... Agent: Seed Intellectual Property Law Group PLLC

20090274689 - Co-administration of a thrombolytic and an anti-cd18 antibody in stroke: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090274694 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department

20090274690 - Human igm antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and... Agent: Klauber & Jackson

20090274693 - Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor: t

20090274691 - Use of cd25 binding molecules in steroid-resistant patients: A method is provided for treating the diseases autoimmune hepatitis, eczema, vasculitis, temporal arteritis, sarcoid and Crohn's disease, in a steroid-resistant or steroid-sensitive patient. The method comprises administering to the patient an effective amount of a CD25 binding molecule and a steroid.... Agent: Dilworth & Barrese, LLP

20090274695 - Inhibition of urokinase-type plasminogen activator (upa) activity: The invention concerns methods for inhibiting the binding of urokinase-type plasminogen activator (uPA) to its receptor uPAR and/or inhibiting uPA biological activity. The invention further concerns methods for inhibiting tumor formation or metastasis, angiogenesis, such as tumor angiogenesis, and screening assays for identifying CYTL1 agonists.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090274696 - Methods for treating inflammation: Provided are methods and compositions for reducing airway hyperresponsiveness and other inflammatory diseases, disorders and conditions in a mammal by decreasing FIZZ1 (Found in Inflammatory Zone 1) activity. Also provided are methods and compositions for identifying modulators of airway inflammation and/or inhibitors of FIZZ1. The present invention encompasses modulators of... Agent: Choate, Hall & Stewart LLP/wyeth

20090274697 - Monoclonal antibodies that specifically block biological activity of a tumor antigen: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”),... Agent: Woodcock Washburn LLP

20090274701 - Chlamydia pneumoniae polynucleotides and uses thereof: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090274698 - Combination anti-cancer therapy: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to... Agent: Osi Pharmaceuticals, Inc.

20090274700 - Il-31 receptor antibodies: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20090274702 - Method of treatment and agents useful for same: The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed... Agent: Morphosys Ag

20090274699 - Ul16 binding protein 4: ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells.... Agent: Immunex Corporation Law Department

20090274703 - Methods of treating inflammation using il-17 antagonists: Aspects of the present invention provide methods for treating diseases associated with IL-17 mediated inflammatory or immunoregulatory reactions.... Agent: Immunex Corporation Law Department

20090274704 - Anti-staphylococcus aureus antibodies: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a Staphylococcus aureus capsular polysaccharide antigen and a constant region that does not bind staphylococcal protein A.... Agent: Strox Biopharmaceuticals, LLC

20090274707 - Anti-il-12 antibodies, nucleic acids encoding antibodies, and methods of production: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090274706 - Antibodies to granulocyte-macrophage colony-stimulating factor: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.... Agent: Townsend And Townsend And Crew, LLP

20090274705 - Il-13 binding agents: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.... Agent: Lando & Anastasi, LLP W2023

20090274708 - Recombinant toxin fragments: e

20090274709 - Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks: Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090274712 - Compositions for coating cell membranes and methods of use thereof: In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy cell therapy to a subject.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090274711 - Levels of blys/april heterotrimers in serum and use in diagnostic methods: The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for... Agent: Alston & Bird LLP

20090274710 - Trans-membrane-antibody induced inhibition of apoptosis: Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090274713 - Cross-linkers and their uses: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.... Agent: Sughrue Mion, PLLC

20090274716 - Lage-1 tumor associated nucleic acids: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.... Agent: Wolf Greenfield & Sacks, P.C.

20090274715 - Tick chitinase: A novel chitinase, a polynucleotide encoding the same, a vector and a transformant comprising the polynucleotide, an antibody against the chitinase, and a screening method for screening a substance capable of modifying the chitinase, are disclosed. According to the chitinase, polynucleotide, or vector, it is possible, for example, to exterminate... Agent: Sughrue Mion, PLLC

20090274714 - Tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090274718 - Chimeric proteins that induce effects directed against viruses: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described... Agent: Hoffmann & Baron, LLP

20090274719 - Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia trachomatis, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090274717 - Genes and proteins, and their use: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090274720 - Anti-dementia substance from hericium erinaceum and method of extraction: A fat-soluble fraction extracted from the fruiting body of Hericium erinaceum is demonstrated to inhibit the neuronal toxicity of amyloid beta-peptide (Aβ) and induce the synthesis of nerve growth factor (NGF), and has great potential as an active ingredient for pharmaceutical products, health food products, food products and/or beverages to... Agent: Simpson & Simpson, PLLC

20090274721 - Compositions comprising hypsizygus ulmarius extract: Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The Hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts.... Agent: The Estee Lauder Cos, Inc

20090274722 - Therapeutic composition for the treatment of bph and ed: The invention relates to a therapeutic composition for the prevention and/or treatment of Benign Prostatic Hyperplasia (BPH) and other related prostate problems. The invention is a therapeutic composition that combines alfalfa and fennel to have a synergistic effect for the treatment of prostate problems, erectile dysfunction, and/or sleep disorders. The... Agent: Summa, Additon & Ashe, P.A.

20090274723 - Modified vaccinia ankara virus vaccine: The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response.... Agent: Nixon & Vanderhye, PC

20090274724 - Novel recombinant and mutant adenoviruses: The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090274725 - Materials and methods for detecting, preventing, and treating retroviral infection: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090274726 - Synthetic gene: The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090274727 - Recombinant rsv virus expression systems and vaccines: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2,... Agent: Medimmune, LLC Patrick Scott Alban

20090274728 - Mutant viruses: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of... Agent: Swanson & Bratschun, L.L.C.

20090274729 - Media for clostridium bacterium and processes for obtaining a clostridial toxin: Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal... Agent: Allergan, Inc.

20090274730 - Compositions and methods for treating inflammation: Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for... Agent: Davis Wright Tremaine, LLP/seattle

20090274733 - Pharmaceutical preparation containing copolyvidone: A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.... Agent: Edwards Angell Palmer & Dodge LLP

20090274731 - Production of enveloped pharmaceutical dosage forms: A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described.... Agent: Edwards Angell Palmer & Dodge LLP

20090274732 - Type-2 diabetes combination wafer: Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the... Agent: D. Peter Hochberg Co. L.p.a.

20090274735 - Flaky particles and luster pigment, and cosmetic, coating composition, resin composition and ink composition each containing the same: Flaky particles of the present invention have a particle size distribution in which a value of D90/D10 is at least 2.0 but not more than 3.0, a value of D10 is at least 4.7 μm but not more than 25 μm, and a maximum particle diameter is 90 μm or... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090274734 - Method for obtaining hollow particles: Described is a method for obtaining hollow particles, having a particle wall and a particle lumen, the particle having dimensions of between 1 nm and 100 μm, from a mixture comprising a liquid medium comprising at least one colloid or solute, the method comprising freezing said mixture and lyophilising the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090274737 - Implant comprising a surface of reduced thrombogenicity: An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of Θ, where Θ≦80°. Also disclosed is a method for producing an implant and the use an implant to reduce the dose or concentration in administration of a concomitant... Agent: Bryan Cave Powell Goldstein

20090274736 - Nutraceutical compositions from microalgae and related methods of production and administration: Provided herein are polysaccharide compositions and methods of culturing microalgae to produce polysaccharides. Also provided are methods of using polysaccharides for applications such as reducing cholesterol in mammals, inactivating viruses, stabilizing foods, and other uses. Also provided are transgenic algae capable of utilizing fixed carbon sources for energy. Also provided... Agent: Townsend And Townsend And Crew, LLP

20090274740 - Drug-loaded medical devices and methods for manufacturing drug-loaded medical devices: Drug-loaded medical devices such as stents and methods for manufacturing them are provided. In certain embodiments, the therapeutic agent is loaded only in or on areas of the medical device that do not undergo substantial deformation during expansion. The medical device may be provided with reservoirs in or on the... Agent: Kenyon & Kenyon LLP

20090274738 - Implantable devices for promoting reendothelialization and methods of use thereof: An implantable device for the controlled delivery of an estrogen receptor agonist to an injured site in the lumen of a mammalian blood vessel, wherein the estrogen receptor agonist is present in an amount of at least about 16.7 μg/mm implantable device length. Methods of use thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090274739 - Methods and compositions for treating neointimal hyperplasia: The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising... Agent: Wilmerhale/columbia University

20090274741 - Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same: Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a polymer comprising a polymeric product of a reaction comprising a polyol, a polycarboxylic acid, an... Agent: Squire, Sanders & Dempsey LLP

20090274743 - Medical devices having a bioresorbable coating layer with a pre-determined pattern for fragmentation: Intravascular medical devices comprising a coating layer disposed on a substrate associated with the medical device, wherein the coating layer has a pre-determined fragmentation pattern. At least a portion of the coating layer comprises a plurality of discontinuous bioresorbable members, wherein the discontinuous bioresorbable members have a size less than... Agent: Kenyon & Kenyon LLP

20090274742 - Multimodal high strength devices and composites: An oriented implantable biodegradable multimodal device is disclosed. The orientated implantable biodegradable multimodal device includes a blend of a first polymer component having a first molecular weight (mwt) together with at least a second polymer component having a mwt which is less than that of the first component. The polymer... Agent: Diana Houston Smith & Nephew, Inc.

20090274744 - Drug delivery system based on cationic siloxanyl macromonomers:

20090274745 - Drug delivery systems based on catonic siloxanyl macromonomers:

20090274746 - Methods and compositions for controlled delivery of phytochemical agents: The presently-disclosed subject matter provides compositions and methods for treating a cancer by providing a composition comprising a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and a chemotherapeutic agent. Further, provided is a device for uterine cervical... Agent: Stites & Harbison, PLLC

20090274748 - Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same: A nonaqueous pressure-sensitive adhesive for a medicinal tape preparation for percutaneous absorption comprising (a) a support, (b) a pressure-sensitive adhesive layer containing a drug and a nonaqueous pressure-sensitive adhesive and (c) a release film laminated in that order, and a medicinal tape preparation for percutaneous absorption comprising the adhesive. The... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090274747 - Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base: A pressure-sensitive adhesive base which contains the liquid organic ingredient and which, despite this, has moderate pressure-sensitive adhesion properties (tackiness and cohesive force) and causes no bleeding. It hardly injures the keratin of the skin and is inhibited from irritating the skin. The pressure-sensitive adhesive base comprises the following ingredients... Agent: Licata & Tyrrell P.C.

20090274752 - Cosmetic and dermatological formulations of mntf peptides: The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.... Agent: Dermacare Neuroscience Institute

20090274754 - Dual action, inhaled formulations providing both an immediate and sustained release profile: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.... Agent: Bozicevic, Field & Francis LLP

20090274751 - Growth factor sensitive vesicle: A generally spherical growth factor sensitive vesicle bearing growth factor receptors (12) having chemical compounds (14) covalently cross-linked to their non-growth factor binding domains. The chemical compounds are capable of associating to form larger chemical compounds (16) capable of destabilizing the vesicle. Methods for treating growth factor-overexpressing neoplasms are disclosed.... Agent: Albert Wong

20090274753 - Ph-sensitive polymeric micelles for drug delivery: Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers... Agent: Alan J. Howarth

20090274750 - Therapeutic treatment of dermatologic skin disorders: Willowherb derivatives are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, willowherb derivates are combined with liposomes to increase the penetration of the willowherb derivates into the skin, to provide hydration of the skin... Agent: Glenn L. Webb Glenn L. Webb P.C.

20090274749 - Topical application for minimizing melanin production: Tyrosinase inhibitors are incorporated with liposomes in therapeutic compositions for topical application to hyperpigmentation. In particular, combinations of tyrosinase inhibitors are combined with liposomes to increase the penetration of the tyrosinase inhibitors into the deep epidermis skin layers and to provide hydration of the skin during treatment.... Agent: Glenn L. Webb Glenn L. Webb P.C.

20090274755 - Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals: The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the... Agent: Kenneth S. Whee Lock

20090274756 - Stabilized composition: It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the... Agent: Birch Stewart Kolasch & Birch

20090274757 - Pharmaceutical polish formulations: Polish compositions for coating pharmaceutical solid dosage forms such as tablets are disclosed. The polish composition comprises water, coating agent, and a film forming agent. Polished pharmaceutical solid dosage forms such as tablets comprising a polished exterior surface are also disclosed. Processes of polishing pharmaceutical solid dosage forms such as... Agent: Pepper Hamilton LLP/wyeth

20090274758 - Solid composition for intra-oral delivery of insulin: The invention provides a solid composition for intra-oral delivery of insulin, comprising; insulin; a hydrophilic polymer matrix; and a phospholipid, providing insulin bioavailability of at least 5%.... Agent: Foley And Lardner LLP Suite 500

20090274759 - Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids: A solid pharmaceutical composition in the form of a single dosage unit for oral use, the composition comprising a first and a second fraction, the first fraction comprises a therapeutically and/or prophylactically active substance dispersed in a dispersion medium that is sufficiently fluid at body temperature and the second fraction... Agent: Foley And Lardner LLP Suite 500

20090274761 - Transdermal delivery of (r)-3,3-diphenylpropylamin-monoestern: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the... Agent: Kenyon & Kenyon LLP

20090274760 - Use of an alkyl glycoside or of a mixture of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and methods of cosmetic care using said compositions: The present invention relates to a novel use of alkyl glycosides and of mixtures of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and to methods of cosmetic care using the said compositions.... Agent: Woodcock Washburn LLP

20090274762 - Rehydratable pharmaceutical product: A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum.... Agent: Sughrue Mion, PLLC

20090274764 - Hollow foam beads for treatment of glioblastoma: Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow... Agent: Philip S. Johnson Johnson & Johnson

20090274763 - Immunoadjuvant: An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b)... Agent: Greenblum & Bernstein, P.L.C

20090274765 - Compositions and methods for drug delivery: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises an opsonin, and the surface-modified particle has... Agent: Marshall, Gerstein & Borun (baxter)

20090274766 - Compositions and methods for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustained enhancement effect on the PPI activity... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20090274767 - Plant protection granulates to be applied to leaf surface: The present invention relates to granules for application to the leaf surface, and to a process for their preparation. The invention furthermore relates to the use of these granules for foliar penetration or the formulation of baits.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090274768 - Fraktionen aus molkepermeat und deren verwendung zur pravention und therapie des typ-2 diabetes und des metabolischen syndroms: Fractions of whey permeate, preferably made, of sweet whey permeate and more preferably of hydrolyzed or partially hydrolyze sweet whey permeate are provided, particularly for use in the production of pharmaceutical compositions, or of food, for the treatment, prophylaxis, or alleviation of glucose intolerance and insulin resistance, and thus of... Agent: Scully, Scott, Murphy & Presser, P.C.

20090274769 - Healing composition: The invention relates to a ternary composition characterized in that it consists of a source of carbohydrates, a source of divided minerals, chosen from clays, and a source of fatty acids. It also relates to a healing composition comprising said ternary composition. In said compositions, the source of carbohydrates is... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090274770 - Cellular extracts: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing... Agent: Casimir Jones, S.c.

20090274771 - Compositions and methods for treating asthma and other lung disorders: Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis,... Agent: Davis Wright Tremaine, LLP/seattle

20090274772 - Disinfectant compositions and methods of use thereof: The present invention discloses a highly potent, non-toxic, disinfectant that can be used for a wide breadth of applications. The disinfectant comprises hydrogen peroxide (H202), orange terpene oil, orange valencia oil, a non-ionic emulsifier (polysorbate 80), and water (H20). Applications of the disinfectant include, but are not limited to, uses... Agent: David S. Resnick

20090274773 - Antiproliferative combination comprising cyc-682 and a cytotoxic agent: A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabi-nofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from (a) a vinca alkaloid; (b) a taxane; (c) a cytosine analogue; (d) an anthracycline; and (e) a platinum antineoplastic agent. A second... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090274774 - Citrate-based dialysate chemical formulations: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090274775 - Lithium combinations, and uses related thereto: The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor... Agent: Foley And Lardner LLP Suite 500

20090274776 - Method for the diagnosis and treatment of conditions involving aberrant erythrocyte potassium levels: The present invention provides a systematic approach that allows health care providers (e.g., physicians) to use erythrocyte potassium measurements as an indicator of hypertension or risk of developing hypertension. In particular, the present invention provides systems and methods for treating conditions involving aberrant erythrocyte potassium levels (e.g., hypertension), preventing the... Agent: Casimir Jones, S.c.

20090274778 - Compositions exhibiting inhibition of cyclooxygenase-2: The invention provides a method of treating diabetes by administering to an individual having diabetes a composition containing a hops extract. In a particular embodiment, an individual having diabetes can be administered a composition comprising a first component selected from the group consisting of alpha acids and beta acids, essential... Agent: Mcdermott Will & Emery LLP

20090274777 - Dietetic composition: (Means for Solving Problems) A dietetic composition characterized by comprising, as the active ingredient, a polar solvent extract of defatted green coffee beans. It is preferable that the above-described polar solvent extract is an extract obtained by using water-containing ethanol, still preferably water-containing ethanol having an ethanol concentration of from... Agent: Clark & Brody

20090274779 - Use in the cosmetics field of an extract of an exsudate of the plant daniellia oliveri, in particular as an antiwrinkle agent: It also relates to a cosmetic care method for modifying the surface of the skin by giving it a smoother appearance through a reduction in the depth of the wrinkles and fine lines and/or by providing it with a re-plumping effect, comprising the application, to the areas of the skin... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090274780 - Menopause treatment composition and regimen: Disclosed are compositions and methods for treating symptoms associated with menopause and/or perimenopause. The compositions are based on a combination of concentrated extracts containing black cohosh, ginseng, red clover, soy isoflavones and St. John's wort, in the form of active compounds of these extracts. The treatment regimen, entail orally administering... Agent: Thaddius J. Carvis

20090274781 - Anti-obesity agent: The present invention provides an anti-obesity agent having an anti-obesity effect obtained by combining a few extracts, which is attained by an anti-obesity agent containing Forsythia leaf extract, Citrus extract, and at least one extract selected from the group consisting of Licorice extract and Gardenia fruit extract, and it is... Agent: Burr & Brown

20090274782 - Anti-obesity agent: The present invention provides an anti-obesity agent having an anti-obesity effect obtained by combining a few extracts, which is attained by an anti-obesity agent (FC) containing Forsythia leaf extract and Citrus extract, and, in addition to these extracts, the anti-obesity agent containing Forsythia leaf extract, Citrus extract, and one extract... Agent: Burr & Brown

20090274783 - Herbal compositions and methods for enhancing vital energy and athletic performance: Compositions, kits and methods are provided for enhancing vital energy and athletic performance, improving or restoring blood circulation, promoting mental acuity, reducing fatigue, and improving aerobic performance. In one embodiment, the composition comprises the herbal extracts of Rhodiola crenulata (root) and Ginkgo biloba (leaf). The composition can be used as... Agent: Wilson, Sonsini, Goodrich & Rosati

20090274784 - Plant extract mixtures and their uses: In one embodiment, a composition containing an effective amount of Cissus quadrangularis and one or more plants selected from the Brillantaisia and Vernonia plant families whereby the composition reduces the amount of fat absorbed or reduces weight in a mammal. Such compositions have beneficial activity principally in controlling weight gain... Agent: Greenberg Traurig LLP (la)

20090263317 - Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease: The invention relates to a screening method for the Smoothened receptor for testing compositions as potential Smoothened receptor ligands, either agonist or antagonist activity, by use of an arrestin-reporter molecule conjugate. It also relates to testing cells and individuals by administering a smoothened receptor ligand-reporter molecule conjugate and observing locations... Agent: Passe' Intellectual Property, LLC

20090263318 - Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer: A novel gene 254P1D6B and its encoded protein, and variants thereof, are described wherein 254P1D6B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 254P1D6B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 254P1D6B gene or... Agent: Agensys C/o Morrison & Foerster LLP

20090263319 - Methods and compositions for treating postoperative pain comprosing ketorolac: Methods and compositions are provided for reducing, treating or preventing postoperative pain or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of ketorolac or pharmaceutically acceptable salt thereof to a target tissue... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263320 - Peptide-based compounds: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.... Agent: Ge Healthcare, Inc.

20090263321 - Compositions and methods for treating post-operative pain using clonidine and bupivacaine: Effective treatments of pain that accompanies post-operative surgeries are provided. Through the administration of an effective amount of a combination of bupivacaine and clonidine at or near a target site, one can alleviate or prevent pain. This administration of bupivacaine and clonidine or pharmaceutically acceptable salts thereof is particularly useful... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263322 - Octahydro-indolizine and quinolizine and hexahydro-pyrrolizines: The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090263323 - Novel means and methods for the treatment of hearing loss and phantom hearing: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with... Agent: Fulbright & Jaworski L.L.P.

20090263324 - Animal model with induced arrhythmia: Provided are a model animal physiologically similar to humans, enabling a highly reproducible evaluation of the onset of drug-induced long QT syndrome, a method of generating the same, and an evaluating method using the same. A proarrhythmia model animal of a monkey, prepared by ablating the atrioventricular node; the foregoing... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090263325 - Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media: Methods and apparatuses that facilitate dissolving a hyperpolarized agent within a polarizer and transporting it to a receiver is provided. The methods include delivering water to a hyperpolarized agent contained within a polarizer, forming a hyperpolarized aqueous solution, transporting the aqueous solution through a fluid path system out of the... Agent: General Electric Company Global Research

20090263327 - Minimally invasive physiological function monitoring agents: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090263326 - Nano-scale contrast agents and methods of use: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20090263331 - Multifunction nanoconjugates for imaging applications and targeted treatment: The present invention relates to nanoconjugates. In particular, the present invention provides nanoconjugates for diagnostic (e.g., imaging), research, and clinical (e.g., targeted treatment) applications.... Agent: Casimir Jones, S.c.

20090263332 - Polymer particle containing paramagnetic metal compound: wherein R1 represents hydrogen atom or methyl group; R2 represents a hydrogen atom or a methyl group; A represents —(CH2)2N+(CH3)3 or the like; and B represents oxygen atom, sulfur atom, —CH2—, or —NH—; and R4 represents hydrogen atom, an optionally substituted alkyl group, or an optionally substituted aryl group, which... Agent: Young & Thompson

20090263329 - Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and spectroscopy: Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled under clinically relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic... Agent: Thompson Coburn LLP Attn: Richard E. Haferkamp

20090263330 - Gas-filled microvesicles with polymer-modified lipids: Image enhancing contrast agents for use in diagnostic and/or therapeutic methods, particularly in the form of gas-filled microvesicles, with enhanced stability. The gas-filled microvesicles are stabilized by a layer of amphiphilic material and comprise from 0.15% to 1.0% by moles of a lipid bearing a hydrophilic polymer. The lipid bearing... Agent: Bracco Research Usa Inc.

20090263328 - Fluorescence observation apparatus and fluoroscopy method: A site of interest to be observed is clearly observed in an image during fluoroscopy of a small laboratory animal, even when the fluorescence is extremely low. The invention provides a fluorescence observation apparatus including a light source that emits excitation light; an optical system that irradiates an image-acquisition site... Agent: Scully Scott Murphy & Presser, PC

20090263334 - Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.... Agent: Borson Law Group, PC

20090263333 - Pharmaceutical compounds and compositions: The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a... Agent: Conley Rose, P.C.

20090263335 - Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease: The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the... Agent: Baker Botts L.L.P.

20090263337 - Detersive compositions containing hydrophobic benefit agents pre-emulsified using sub-micrometer-sized insoluble cationic particles: A cationic oil-in-water emulsion, for addition to detersive compositions, comprising hydrophilic cationic polymers, a surface-active, anionic polymer that is capable of adsorbing at an air-water interface or an oil-water interface and/or is oil-soluble, and a hydrophobic benefit agent in the oil phase made by adding the benefit agent to a... Agent: Marshall, Gerstein & Borun LLP

20090263336 - Novel pyran derivatives and their preparation: c

20090263338 - Nail varnish: Nail varnish composition in the form of an emulsion containing one or more water-soluble or water-dispersible polymers obtained from acrylamido-2-methylpropanesulphonic acid (or AMPS) or from one of its salts and from water-soluble monomers having ethylenic unsaturation(s) as gelling agent. Makeup method employing the composition. Dried films of the nail varnish.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263339 - Agent for external application to the skin: The present invention has an object to provide an agent for suppressing melanin production and/or inhibiting elastase activity containing a plant extract as an effective substance with high safety and acceptable levels of stability and odor or sediment formation and an agent for external application to the skin comprising the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090263340 - Cosmetic compositions: The present invention relates to cosmetic or dermatological compositions comprising salicylic acid, optionally substituted salicylic acid and/or derivatives thereof and ascorbic acid and/or derivatives thereof in a cosmetically acceptable carrier. The salicylic acid, optionally substituted salicylic acid and/or derivatives thereof serve as skin penetration enhancer for the ascorbic acid and/or... Agent: Nixon & Vanderhye, PC

20090263341 - Soft anticholinergic esters: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X− is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the... Agent: Buchanan, Ingersoll & Rooney PC

20090263342 - Non-lathering personal care composition in the form of an article: A non-lathering personal care article in the form of a porous dissolvable solid structure, comprising: from about 0% to about 10% ionic surfactant; from about 1% to about 60% of a non-surfactant cosmetic active; from about 15% to about 70% polymeric structurant, wherein the polymeric structurant has a weighted average... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090263343 - Deodorized cloth and method for deodorizing cloth: Disclosed is a deodorized cloth which is produced by applying a deodorizing agent comprising active carbon and an amine compound in two layers on a cloth, thereby providing a durable deodorizing property against any type of odor to the cloth. Also disclosed is a method for deodorization processing of a... Agent: Kirschstein, Israel, Schiffmiller & Pieroni, P.C.

20090263344 - Perfume compositions: Perfume compositions effective against urine malodour and having a low odour, comprise between 20% and 50% of perfume ingredients comprising at least 15% by-weight of N-ethyl-N-(3-methylphenyl) propanamide.... Agent: Norris, Mclaughlin & Marcus

20090263345 - Otic compositions for the treatment of infections of the internal and external ear in mammals: Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans.... Agent: Morgan, Lewis & Bockius LLP

20090263346 - Systems and methods for delivery of drugs: Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively... Agent: Bell & Associates

20090263347 - Analysis of amino acid copolymer compositions: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the... Agent: Fish & Richardson PC

20090263348 - Nucleic acids encoding multimeric fusion proteins of tnf superfamily ligands: A method for constructing stable bioactive fusion proteins of the difficult to express turn or necrosis factor superfamily (TNFSF), and particularly members CD40L (CD 154) and RANKL/TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural... Agent: Dla Piper LLP (us)

20090263350 - Cosmetic and dermatological methods: The present invention relates to cosmetic and dermatological methods for treating cellulite, reducing signs of aging skin, and treating stretch marks, the methods comprising applying/administering to the skin of a subject in need thereof the compositions comprising interleukin-1 alpha.... Agent: Notaro & Michalos P.C.

20090263349 - Methods and compositions for inhibiting angiogenesis: The present invention relates to a method of inhibiting angiogenesis in a biological system. The method includes administering to the biological system an effective amount of a steroid saponin.... Agent: Klarquist Sparkman, LLP

20090263352 - Methods for treating viral infection using il-28 and il-29 cysteine mutants: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20090263351 - Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid... Agent: Wyeth/finnegan Henderson, LLP

20090263353 - Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles: t

20090263354 - Compositions and sirnas for inhibiting c/ebpbeta: The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090263355 - Deamidated interferon-beta: Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in... Agent: Novartis Corporate Intellectual Property

20090263364 - Method and constructs for delivering double stranded rna to pest organisms: The present invention relates in generally to RNAi and its use in gene silencing. In particular, the present invention relates to methods and constructs for delivering double stranded RNA (dsRNA) to pest organisms.... Agent: Wolf Greenfield & Sacks, P.C.

20090263365 - Methods and compositions for transforming dendritic cells and activating cells: Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by... Agent: Townsend And Townsend And Crew, LLP

20090263356 - Anti-angiogenic composition comprising grain-derived component as active ingredient: It is an object of the invention to provide a composition with an excellent action of inhibiting vascularization, as prepared by a simple method suitable for actual production from an inexpensive, relatively readily available material without any problematic safety profile at an industrial scale without any complicated purification step. The... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090263366 - Effects of probiotics on humans and animals under environmental or biological changes: An exemplary embodiment providing one or more improvements includes probiotic compositions comprising probiotic microorganisms with dried vegetable, fruit, cereal, or herb powder. Feeding human or animals either having biological or environmental changes with probiotic compositions has a positive effect in relieving the changes. Positive effects has been demonstrated in humans,... Agent: William S Ramsey, Esq

20090263363 - Compositions and methods for treating bone formation disorders: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone... Agent: Casimir Jones, S.c.

20090263362 - Fertility enhancement using lipid carriers and bioactive molecules: The invention relates to a composition and method for enhancing fertilization. Fertilization enhancement is achieved by effectively delivering bioactive molecules with a lipid anchor (GPI-linked proteins) to the surface of epididymal or ejaculated sperm. The process may be facilitated or promoted in the presence of Clusterin/APOJ, a well-known lipid carrier.... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090263361 - Human trophoblast stem cells and use thereof: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive... Agent: Wilson, Sonsini, Goodrich & Rosati

20090263358 - Method for treating multiple myeloma: The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.... Agent: Bozicevic, Field & Francis LLP

20090263360 - Neuronal progenitors from feeder-free human embryonic stem cell culture: The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and... Agent: Coleman Sudol Sapone, P.C.

20090263359 - Particulate delivery vehicles for embryoid bodies: The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces... Agent: Choate, Hall & Stewart LLP

20090263357 - Therapeutic reprogramming, hybrid stem cells and maturation: Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy... Agent: K&l Gates LLP

20090263367 - Composition and method for promoting internal health and external appearance: The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and/or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect... Agent: Miller Thomson LLP

20090263369 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as... Agent: Jones Day

20090263368 - Genetic variations associated with psychiatric disorders: The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder. More particularly, the method of the invention is based on the identification of genetic variations in genes involved in the modulation of melatonin and their consequences on such pathway for the determination... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263370 - Methods for treating tachykinin-mediated diseases with cholinesterase: Methods for treating or preventing a tachykinin-mediated disease, a skin disorder, or a symptom thereof in a mammal by administering to a mammal in need thereof cholinesterase or a pharmaceutical composition of cholinesterase.... Agent: Matthias Scholl

20090263372 - Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC

20090263371 - Use polysaccharides for promotion of enzymatic activity: This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090263373 - Non-neurotoxic plasminogen activating factors for treating of stroke: The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090263374 - Method of preventing and treating brain infarction: The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present invention relates to a method of preventing and treating cerebral infarction by activating PAR-2... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090263376 - Breaking immunological toterance with a genetically encoded unnatural amino acid: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against... Agent: Quine Intellectual Property Law Group, P.C.

20090263377 - Il-32b-targeted diagnosis and therapy: Methods for the diagnosis and treatment of IL-32β over-expressing cancers are provided. Also provided are methods for the treatment of wounds, hair loss and the promoting and/or restoration of hair growth utilized IL-32β antagonists. Finally, a sepsis model utilizing IL-32β is provided, as are methods for treating sepsis and inflammation... Agent: Fulbright & Jaworski L.L.P.

20090263378 - Methods of identifying anti-inflammatory compounds: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090263379 - Monoclonal antibodies for inhibition of laminin-8 expression to inhibit human gliomas: Using gene array technology, we observed that an increase of the alpha-4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop... Agent: Davis Wright Tremaine LLP/los Angeles

20090263375 - Novel poly(a) polymerase: The present invention relates to novel poly(A) polymerases and their use in the treatment of diseases, disorders and conditions. More specifically, the poly(A) polymerases of the present invention include polymerases which are directly modulated by components of the phosphoinositide signaling pathway. Such components may include phosphatidylinositol phosphate kinases and phosphoinositide... Agent: Wisconsin Alumni Research Foundation (warf)

20090263380 - Anti-idiotypic antibodies neutralizing the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090263381 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and... Agent: Wilson, Sonsini, Goodrich & Rosati

20090263384 - Agents for suppressing the induction of cytotoxic t cells: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6... Agent: Fish & Richardson PC

20090263391 - Antibodies that bind to epha2 and methods of use thereof: Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.... Agent: Morrison & Foerster LLP

20090263383 - Antibodies to angiogenesis inhibiting domains of cd148: The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen... Agent: Amgen Inc. Law Department

20090263385 - Breast carcinoma treatment method: The instant invention is an in-vivo treatment method directed against living epithelial cells in the human breast, and uses a modified ductal lavage technique to infuse a purposely formulated treatment fluid into pre-chosen individual ducts in the human breast for reaction with such epithelial cells as then are present within... Agent: David Prashker P.C.

20090263386 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.... Agent: Winston & Strawn LLP Patent Department

20090263390 - Method of treating cancer by co-administration of anticancer agents: The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin -2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing... Agent: Sughrue Mion, PLLC

20090263388 - Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists: A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.... Agent: Cooper & Dunham, LLP

20090263387 - Neutralization of gm-csf for the treatment of heart failure: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.... Agent: Townsend And Townsend And Crew, LLP

20090263382 - Stable and soluble antibodies inhibiting tnf alpha: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis... Agent: Marshall, Gerstein & Borun LLP

20090263389 - Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection: Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of... Agent: Genzyme Corporation Legal Department

20090263392 - Methods of modifying antibodies for purification of bispecific antibodies: The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of... Agent: Fish & Richardson PC

20090263394 - A34 and a33-like 3 dna protein, antibodies thereto and methods of treatment using same: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a... Agent: Crowell & Moring LLP Intellectual Property Group

20090263393 - Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for... Agent: Jones Day

20090263395 - Genes and polypeptides relating to breast cancers: The present application provides novel human genes B1194, A2282V1, A2282V2, and A2282V3 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer.... Agent: Townsend And Townsend And Crew, LLP

20090263396 - Inhibitors of t-darpp for use in combination anti-cancer therapies: The present invention relates to an improved anti-HER2/Neu therapy comprising co-administration of an inhibitor of t-DARPP activity. In addition, inhibitors of t-DARPP can act as a monotherapy against cancers that express elevated t-DARPP activity, including elevated t-DARPP levels, or in combination with chemo- or radiotherapeutic anti-cancer treatments drugs.... Agent: Fulbright & Jaworski L.L.P.

20090263397 - Combination anti-cancer therapy: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula... Agent: Osi Pharmaceuticals, Inc.

20090263399 - Method for establishing the sensitivity of tumours to capecitabin and test kit: e

20090263400 - Osteoporosis associated markers and methods of use thereof: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.... Agent: Marshall, Gerstein & Borun LLP

20090263398 - Pharmaceutical combinations: The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9(C═O) or 0(C═O) wherein... Agent: Heslin Rothenberg Farley & Mesiti PC

20090263402 - Growth differentiation factor-11: A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-11 (GDF-11) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods... Agent: Dla Piper LLP (us)

20090263401 - Uses of il-174 antagonists for inhibiting a th2 immune response: Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090263403 - Mammalian cell membrane proteins; related reagents: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.... Agent: Schering-plough Biopharma Legal Department

20090263404 - Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor,... Agent: Law Office Of John K. Pike, PLLC

20090263407 - Cationic lipids and uses thereof: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090263405 - Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods: The present invention provides a CpG oligonucleotide prodrug that includes a thermolabile substituent on at least one nucleotide thereof. The present invention also provides compositions that include a carrier and a therapeutically effective amount of at least one CpG oligonucleotide prodrug. The present invention further provides therapeutic methods of using... Agent: Leydig, Voit & Mayer, Ltd.

20090263408 - Formulation and presentation of medicaments: A medicament package (10,30) comprises a vessel (12,32) adapted to hold a quantity of a liquid vehicle. The vessel (12,32) has an opening formed therein, to which opening is bonded a deformable enclosure (18,38). A medicament container (20) that contains a unit dose of a medicament is received within the... Agent: Woodling, Krost And Rust

20090263406 - Jy-1 regulation of granulosa cell function and early embryonic development in cattle: The present invention provides compositions and methods for regulating fertility in mammals. In general, the invention relates to a novel protein produced by oocytes named JY-1, and nucleic acids encoding the JY-1 protein, for controlling folliculogenesis and early embryonic development, particularly in monoovulatory species. In particular, the present invention provides... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090263409 - Cancer antigen peptide formulations: The invention relates to water-in-oil emulsions which comprise as an effective ingredient either one or both of peptides selected from the group consisting of a peptide having an amino acid sequence of Cys Met Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 2), and a peptide having an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263411 - Compositions, splice variants and methods relating to ovarian specific genes and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.C.

20090263410 - Use of tgf-b1 inhibitor peptides in the preparation of an immune response modulating agent: The present invention relates to the use of a peptide inhibiting TGF-β1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the... Agent: Moore & Van Allen PLLC

20090263412 - Non-splicing variants of gp350/220: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use... Agent: Medimmune, LLC Patrick Scott Alban

20090263413 - Immunostimulatory oligonucleotides and use thereof in pharmaceuticals: A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (X... Agent: Birch Stewart Kolasch & Birch

20090263414 - Bifunctional protein anchors: The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional... Agent: Traskbritt, P.C.

20090263415 - Composition for scalp and hair of scalp: An object of the present invention is to provide scalp and hair of scalp composition which realizes hair growing, hair growth or the like by arranging the scalp environment without inhibiting the function of sebaceous membrane and dark cell (superficial type cell) of scalp. To achieve the object, the present... Agent: Ladas & Parry LLP

20090263416 - Reduction of antibiotic resistance in bacteria: In one aspect of the present invention, a method is provided for reducing or eliminating antibiotic resistance in bacteria, comprising exposing the bacteria to a composition comprising a yeast cell wall preparation in an amount effective for reducing or eliminating resistance of the bacteria to at least one antibiotic. In... Agent: King & Schickli, PLLC

20090263417 - Multi-subtype fiv vaccines: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090263419 - Live attenuated bacterial vaccine: A live, attenuated bacterium of the genus Escherichia, Yersinia or Salmonella, that does not have a functional tRNA5leu, and vaccines comprising the live, attenuated bacterium.... Agent: Intervet/schering-plough Animal Health

20090263418 - Means and methods for manipulating sequential phagolysomalcytosolic translocation of mycobacteria, and uses thereof: Mycobacteria such as M. tuberculosis and M. leprae are considered to be prototypical intracellular bacilli that have evolved strategies to enable growth in the intracellular phagosomes of the host cell. By contrast, we show that lysosomes rapidly fuse with the virulent M. tuberculosis and M. leprae— containing phagosomes of human... Agent: Rissman Hendricks & Oliverio, LLP

20090263420 - Virus-like particles as vaccines for paramyxovirus: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090263421 - Cellular vaccine: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T... Agent: Dann, Dorfman, Herrell & Skillman

20090263423 - Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc): This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious... Agent: Dla Piper LLP (us)

20090263422 - Influenza vaccine: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090263424 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090263425 - Methods of stimulating an immune response against prostate specific antigen: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for... Agent: Leydig, Voit & Mayer, Ltd.

20090263426 - Methods for treating headache: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the... Agent: Allergan, Inc.

20090263427 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20090263428 - Artificial lymph node for treating cancer: A method of producing an artificial lymph node capable of inducing cancer antigen-specific immune responses, comprising the following steps: (a) a step for immunizing a non-human animal using a cancer antigen and an adjuvant capable of inducing cellular immunity; and (b) a step for transplanting an artificial lymph node material... Agent: Leydig Voit & Mayer, Ltd

20090263429 - Method of preparing a hydrogel: A method of preparing a hydrogel comprises: (i) reacting a first molecule comprising a carboxylic acid group and second molecule comprising an amine group or an alcohol group with a hydrolase enzyme to form a product comprising an amide bond or ester bond, wherein the hydrolase enzyme would normally catalyse... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090263430 - Multilayer silk protein films: The present invention is directed to a method of forming multilayer silk protein films and a multilayer film obtained therefrom. The invention is further directed to various materials, products and compositions containing said multilayer film and to the use of Said multilayer film in several applications.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090263431 - Polyurethane foams for wound management: The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and specific coagulants is frothed and dried.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090263432 - Stable combinations of amlodipine besylate and benazepril hydrochloride: The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same.... Agent: Kenyon & Kenyon LLP

20090263435 - Compositions and methods for minimizing and/or reducing the appearance of defects around eyes: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263433 - Cosmetic composition: Provided are a cosmetic composition which is an O1/W/O2 emulsion composition and contains, in the oil phases O1 and O2 thereof, fine metal oxide particles having ultraviolet screening ability; and a preparation process of the cosmetic composition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263434 - Powder composed of inorganic compound-loaded polyamide porous particle: Powder composed of fine inorganic compound particles-deposited porous polyamide particles in which the inorganic compound particles are deposited on surfaces and in pores of the porous polyamide particles, the porous polyamide particle have a mean primary particle diameter in the range of 1 to 30 μm, the fine inorganic compound... Agent: Nixon Peabody, LLP

20090263436 - Material primarily for medical, long-term in vivo use, and method for the production thereof: The invention relates to a material that is used primarily for medical, long-term in vivo purposes, e.g. as a filling material in dentistry. The aim of the invention is to create a material primarily for medical, long-term in vivo use which does not have the disadvantages of materials used in... Agent: Jordan And Hamburg LLP

20090263437 - Pesticide compositions: The present invention provides a granular pesticide composition which is highly effective in controlling pests. In particular, the pesticide composition of the present invention is prepared by adsorbing an oil in water emulsion on inert granular particles. These compositions provide improved release of the pesticide. Methods of preparing the granular... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090263438 - Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives: Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.... Agent: Myers Bigel Sibley & Sajovec

20090263439 - Antimicrobial preservative free wipe: A mild and gentle antimicrobial active wet wipe comprising a substrate and a lotion with a pH that ranges from 2.5 to 5.4 and contains no chemical preservatives.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090263440 - Disposable containers and utensils for sanitizing: A disposable container and/or utensil including an uncoated portion and a coated portion. The coated portion includes antibacterial agents and covers a substantially larger external surface area of the disposable container than the uncoated portion. The coated container includes, but is not limited to, a cup, a cup sleeve, or... Agent: Yvette Kendall

20090263441 - Drug depots having diffreent release profiles for reducing, preventing or treating pain and inflammation: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263444 - Fluocinolone formulations in a biodegradable polymer carrier: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263445 - Medical devices comprising spray dried microparticles: An implantable or insertable medical device which includes (a) a tacky polymeric region and (b) spray dried microparticles, which are adhered to the tacky polymeric region. The present invention is further directed to methods of forming such medical devices, and methods of releasing a therapeutic agent within a patient using... Agent: Mayer & Williams PC

20090263443 - Methods for treating post-operative effects such as spasticity and shivering with clondine: Effective treatments of spasticity and shivering that accompanies surgeries are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relax muscle fibers. This administration of clonidine or a pharmaceutically acceptable salt thereof is particularly useful following the surgery.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263442 - Post biopsy cavity treatment implants and methods: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second... Agent: Young Law Firm, P.C. Alan W. Young

20090263450 - Alpha adrenergic receptor agonists for treatment of inflammatory diseases: Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263451 - Anti-inflammatory and/or analgesic agents for treatment of myofascial pain: Effective treatments of myofascial pain and/or inflammation are provided. Through the administration of an effective amount of at least one anti-inflammatory agent and/or analgesic at or near a target site, one can reduce, prevent or treat myofascial pain and/or inflammation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263448 - Clonidine formulation in a polyorthoester carrier: Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263447 - Crosslinked hyaluronic acid and process for the preparation thereof: f

20090263449 - Delivery of nucleic acid complexes from materials including negatively charged groups: Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a medical device including a substrate surface, a polymeric coating disposed on the surface, the polymeric coating coupled to the substrate surface through the reaction product of... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090263452 - Drug-eluting intravascular prostheses and methods of use: The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090263446 - Method of making load bearing hydrogel implants: Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of... Agent: Knobbe Martens Olson & Bear LLP

20090263454 - Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist and at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263453 - Methods and compositions for treating pain comprising a statin: Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263461 - Alpha adrenergic receptor agonists for treatment of degenerative disc disease: Effective treatments of pain and/or inflammation from degenerative disc disease and/or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and/or facet joint, one can reduce, prevent or treat pain and/or inflammation caused by the... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263463 - Alpha adrenergic receptor agonists for treatment of pain and/or inflammation: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263465 - Biopolymer-bioengineered cell sheet construct: A biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient is recited. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet containing a monolayer of interconnected HCECs with substantially uniform orientation. The bioengineered cell sheet is attached... Agent: Bacon & Thomas, PLLC

20090263464 - Bladder reconstruction: The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of... Agent: David S. Resnick

20090263457 - Block copolymer comprising at least one polyester block and a poly(ethylene glycol) block: The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20090263455 - Dexamethasone formulations in a bioegradable material: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263458 - Material for surgical use in traumatology: The present invention relates to a material, structure, and method for surgical use in traumatology. More particularly, the present invention relates to a composite material, a temporary biocompatible support structure, and related methods of use of the same in aiding osteosynthesis during healing of a bone fracture. The material keeps... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090263460 - Medical devices and methods including polymers having biologically active agents therein: The implant design is a drug loaded polymer device, such as a rod, designed to control the release of a biologically active agent, such as clonidine or its derivatives, such as clonidine HCl for a prolonged period of time, such as 2 months, 3 months, 4 months, and even 4.5... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263456 - Methods and compositions for reducing preventing and treating adhesives: Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid or pharmaceutically acceptable salt thereof to a target tissue site beneath... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263459 - Methods and compositions for treating intervertebral disc herniations: Methods and compositions are provided for treating an intervertebral disc herniation by local administration of one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid at or near the intervertebral disc herniation to reduce the size of the intervertebral disc herniation.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263462 - Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine: Effective treatments of dystonia and/or post-stroke spasticity for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve dystonia and/or post-stroke spasticity caused by diverse sources. When appropriate formulations are provided within biodegradable polymers, this relief... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263466 - Herbal composition for treatment of hyperlipidemia and the inhibition of myocardial infarction: A pharmaceutical or medicinal herbal composition and method of making the composition comprised of a mixture of the following herbal ingredients: Glycine max, Plumbago zeylanica, Terminalia arjuna, Trigonella-foenum-graceum, Coleus forskohlii, Commiphora mukul, Camellia sinensis, and Azadirachta indica.... Agent: Volpe And Koenig, P.C.

20090263467 - Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments: A combination drug therapy can be administered to patients to treat xerostomia or dry mouth or Sjogren's syndrome in the form of orally dissolving film or orally disintegrating tablets. Some of the drugs could be synthetic origin and some drugs are obtained from natural sources.... Agent: Hemant N. Joshi/tara Enterprises

20090263468 - Methods and compositions for wound healing: The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely... Agent: Casimir Jones, S.c.

20090263469 - Biguanide-containing liposomes: The present invention relates to biguanide-containing liposomes and antiseptic preparations based on biguanide-containing liposomes, where the liposomes are characterised in that they are essentially free of lipids with anionic head groups, to the preparation of biguanide-containing liposomes and of the antiseptic preparations, and to their possible uses and to the... Agent: Panitch Schwarze Belisario & Nadel LLP

20090263471 - Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof: Herein is described a controlled release pharmaceutical composition of venlafaxine hydrochloride, an effective antidepressant, comprising an inert core; on which the active principle is uniformly layered, that in turn is coated with a layer comprising a hardening agent and a lipophilic agent; the process for the preparation of said pharmaceutical... Agent: Stetina Brunda Garred & Brucker

20090263472 - Endothelin receptor antagonist derivatives: r

20090263474 - Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays: The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk... Agent: Brinks, Hofer, Gilson & Lione

20090263473 - Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same: The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according... Agent: Swanson & Bratschun, L.L.C.

20090263470 - Vaccine compositions comprising virosomes and a saponin adjuvant: This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090263475 - Dexlansoprazole compositions: Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.... Agent: Dr. Reddy''s Laboratories, Inc.

20090263476 - Composition of rapid disintegrating direct compression buccal tablet: A composition of a rapidly disintegrating buccal dosage form containing a drug, at least one non-effervescent base such as an alkali metal or alkaline earth metal oxide or hydroxide, and a disintegrant. The base regulates the pH gradient to deliver the drug to the buccal, sublingual or oral mucosal membranes... Agent: St. Onge Steward Johnston & Reens, LLC

20090263477 - Salts of fenofibric acid and pharmaceutical formulations thereof: c

20090263478 - Carvedilol forms, compositions, and methods of preparation thereof: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.... Agent: Cantor Colburn, LLP

20090263479 - Formulations for poorly permeable active pharmaceutical ingredients: The present invention relates to a pharmaceutical oral dosage form containing a poorly permeable active pharmaceutical ingredient and at least one permeability improving substance, wherein the permeability improving substance is thermostably embedded in a water-soluble matrix of a water soluble carrier, and to thermostable formulations which can be used to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090263480 - Taste-masked pharmaceutical compositions prepared by coacervation: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090263481 - Levetiracetam formulations: Pharmaceutical formulations comprising levetiracetam and having an inner solid phase and outer continuous phase, wherein one or both of the phases comprise at least one hydrophobic material, lipophilic material, or combination thereof.... Agent: Dr. Reddy''s Laboratories, Inc.

20090263482 - Treatment of inflammatory bowel disease with 6-mercaptopurine: Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine... Agent: Kenyon & Kenyon LLP

20090263483 - Nanoparticle formulations and uses thereof: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.... Agent: Morrison & Foerster LLP

20090263484 - Tissue engineering devices and methods for luminal organs: Tissue engineering devices and methods are provided for the reconstruction, repair, augmentation, or replacement of a luminal organ or tissue structure involving the use of a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ, the processing of autologous, allogeneic or xenogeneic tissue comprising multiple cell... Agent: Philip S. Johnson Johnson & Johnson

20090263487 - Bubble drink provided by bubbling engineering progress: A bubble drink as a health food, which is produced by imparting a catalytic function for gas escaping to an adsorptive fine food powder to allow the fine food powder to be dispersed in a colloidal solution reverse vessel, and reacting the dispersion with a gas-saturated solution to generate foam... Agent: The Nath Law Group

20090263486 - Nanoparticle-stabilized capsule formulation for treatment of inflammation: A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide) stabilised by nanoparticles, particularly silica nanoparticles.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090263488 - Pressurised metered dose inhalers containing solutions of beta-2 agonists: The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β2-agonists by inhalation. In particular this invention relates to a chemically stable highly efficient TA 2005 HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090263485 - Targeted hollow gold nanostructures and methods of use: Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are... Agent: Bell & Associates

20090263489 - Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation: Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263490 - Microsphere beeswax for mammalian dietary fat mitigation: A device composed of a plurality of beeswax microspheres are contained within a digestible capsule intended for the alimentary tract of the mammal. A method in which the device is ingested orally into the digestive system. A method in which digestive enzymes remove the outside capsule and beeswax microspheres are... Agent: Allan Y. Wu

20090263491 - Polylactide nanoparticles: A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles,... Agent: D. Peter Hochberg Co. L.p.a.

20090263492 - Diagnostic methods and genetic markers for alzheimer disease: Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy... Agent: Jones Day

20090263493 - Method for making synthetic slug slime and medical use of synthetic and or actual slug slime: The device hereof is most preferably the use of the slime coating of slugs or a synthetic copy of the slug slime, healing agents such as steroids antibiotics, growth hormones or pain killers can be mixed is with the slime before application to a burned or infected area. The slime... Agent: George W. Dishong Esq. Dishong Law Office

20090263494 - Manzanita: Applying the bark of the mariposa Manzanita shrub either mixed into a hot tea or added to mayonnaise and zinc for open sores will cure the herpes virus.... Agent: Robert Emerson

20090263495 - Bacteriostatic or bacteriocidal compositions and methods: Particular aspects provide compositions and methods for treating or preventing bacterial infection or at least one symptom related to bacterial infection, and the like in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein,... Agent: Davis Wright Tremaine, LLP/seattle

20090263496 - Method for producing metal particles, metal particles produced thereby, and the use thereof: r

20090263497 - Production method for calcium phosphate nano-particles with high purity and their use: The present invention provides a continuous process for producing calcium phosphate nanoparticles in a network mixer or static mixer reactor, fed by a calcium solution, a phosphorous solution and an alkaline solution and, optionally, one solvent or dispersing agent. The proposed process enables the micromixing control, which is essential to... Agent: Sughrue Mion, PLLC

20090263498 - Pharmaceutical preparations for treating inflammatory diseases: e

20090263501 - Activated oxidizing vapor treatment system and method: An oxidizing liquid (20), such as hydrogen peroxide, is vaporized (18) and the vapor is used to deactivate nerve gas, blistering gas, or other biologically active substances such as pathogens, biotoxins, and prions. A second chemical compound (42) in vapor, mist, or fog form is used in conjunction with the... Agent: Fay Sharpe LLP

20090263499 - Area decontamination via low-level concentration of germicidal agent: Provided is a method of decontaminating an area, and related device. The method comprises releasing a germicidal agent into the area from a germicidal source, controlling the germicidal agent concentration in the area to a predetermined concentration that does not exceed a Permissible Exposure Limit, and contacting microorganisms in the... Agent: K&l Gates LLP

20090263500 - Composition and method for treating bedsores, cuts and burns: The invention provides a composition and method to prevent and treat bedsores rapidly, efficaciously and economically. The composition comprises a novel combination of herbal extracts that has surprisingly synergistic and highly efficacious effects for the acceleration of wound healing, and which also disinfects and relieves pain in dermal wounds. The... Agent: F. Russell Denton, Ph.d., Esq.

20090263502 - Highly dispersible titanium dioxide powder: Provided is a means for controlling a plant disease or a pest insect by utilizing a highly dispersible titanium dioxide powder produced by a discharge treatment of a titanium dioxide powder. Titanium dioxide is a substance which is highly safe to living organisms and the environment. A plant disease or... Agent: Birch Stewart Kolasch & Birch

20090263503 - Compositions for cleaning contained bodies of water with metal hydrates: Compositions for cleaning, sanitizing and maintaining contained bodies of water such as swimming pools, wading pools, fountains, ornamental ponds, etc. The compositions include pre-determined percentages of hydrates of copper sulfate, zinc sulfate, and aluminum sulfate by weight. The composition uses hydrates of copper, zinc and aluminum sulfates instead of the... Agent: Lesavich High-tech Law Group, P.C.

20090263504 - Methods and compositions for promoting activity of anti-cancer therapies: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.... Agent: Klarquist Sparkman, LLP

20090263505 - Dietary therapeutic compositions for ameliorating disease symptoms and conditions associated with diabetes: A daily dietary supplement for improving glucose metabolism, said dietary supplement comprising: an effective amount of a source of Alpha Lipoic Acid; an effective amount of a source of Salacia Oblonga; an effective amount of a source of Gymnema Sylvestre; an effective amount of a source of Chromium; an effective... Agent: Michael Ries

20090263506 - Calcareous organism growth accelerator: The purpose of this invention is to provide compositions useful for promoting the growth of calcareous organisms present in a closed system aquatic habitat. Particularly, to composition capable of efficiently delivering calcium and carbonate to the calcareous organisms. Most particularly, to a composition effective for enhanced delivery of aragonite to... Agent: Mchale & Slavin, P.A.

20090263507 - Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use: The invention provides methods and kits for treatment of pain, inflammation, neuronal or vascular injury and the use of biomarkers for the assessment of the biological activity or disease state. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, a bioactive agent, such as a magnesium... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090263508 - micronutrient supplement with calcium, vitamin d or calcium & vitamin d combination for premenstrual syndrome, postpartum depression, depression and panic attacks: A bolus dose supplement, foodstuff, beverage and beverage concentrate with calcium and vitamin D for the treatment and prevention of PMS, panic attacks, and postpartum depression. The combination of adequate calcium and vitamin D is provided as a multi-vitamin and mineral supplement. The bolus dose is comprised of 2 main... Agent: Gottlieb Rackman & Reisman PC

20090263509 - Antibacterial agent and antibacterial composition: The problems to be solved by the invention are to provide antibacterial agents originated from natural products that are safe for regular use with potent antibacterial activity, and antibacterial compositions containing said antibacterial agents. Antibacterial agents containing Eysenhardtia adenostylis extract or isoflavan compounds are a solution to the problem. Also... Agent: Brooks Kushman P.C.

20090263512 - Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090263511 - Insecticidal composition: The use of dill oil or a mixture of two or more components thereof as a potentiator for a pesticide, such as an insecticide and in particular a pyrethroid is described, together with compositions containing dill oil, and their use in agriculture and in veterinary applications.... Agent: Intellectual Property / Technology Law

20090263510 - Process of making hoodia plant extract with improved flavor: Processes of making extracts of Hoodia plant containing steroidal glycosides which have improved flavor, by virtue of reduced Levels of discovered negative flavor compounds.... Agent: Unilever Patent Group

20090263513 - Cosmetic skin lightening formulation: The present invention features novel cosmetic skin care compositions for lightening hyperpigmentation.... Agent: Bozicevic, Field & Francis LLP

20090263514 - Cold and flu tonic: A method and composition for reducing the symptoms of the common cold and flu in a human subject in need thereof, comprising the administration of an effective amount of an aqueous composition having all components dispersed as a dry powder concentrate or dissolved in a decoction therein comprising Black pepper,... Agent: Govindan Gopinathan, Md

20090263515 - Pest repellent compositions and methods: The invention is directed to a topical insect repellent with extended duration of protection and that was obtained by combining natural and organic plant essential oil compounds. The new natural repellent exhibits the longevity and repellency that is comparable to or better than N,N-diethyl-m-toluamide (DEET), a synthetic compound employed in... Agent: Nixon & Vanderhye, PC

20090263516 - Plant extract composition and their use to modulate cellular activity: Extracts from plant material, or semi-purified/purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus,... Agent: Sheppard, Mullin, Richter & Hampton LLP

20090263517 - Method for producing margosa extract: The invention relates to a method for producing a margosa extract, an oil from cores and/or seeds of the neem tree being used and the oil being extracted using a carbon dioxide-containing extracting agent. The invention further relates to a margosa extract as is obtained using the method, its use... Agent: Scott R. Cox Lynch, Cox, Gilman & Mahan, P.s.c.

20090263519 - Composition and methods for inducing the expression of heat shock proteins: A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and/or paeoniflorin or derivative of paeoniflorin and an effective amount of Schisandrin B, wherein the ingredients act substantially simultaneously, via differing mechanism, to enhance the expression of heat shock protein in cells, particularly heat shock... Agent: Iovate Health Science Research Inc.

20090263518 - Composition and uses thereof: A composition for topical application to the skin comprises a cocoa polyphenol extract in combination with an SUS-rich fat, wherein the cocoa polyphenol extract is present in an amount of less than 15% by weight based on the weight of the SUS-rich fat, and a cosmetically acceptable carrier. The composition... Agent: Hoxie & Associates LLC

20090263520 - Nematicidal composition: A nematicidal composition comprising (i) one or more essential oils selected from Tagetes erecta oil, Ocimum basilicium (sweet basil) oil or a Cymbopogon martini (palmerosa) oil, or a mixture thereof, or certain components thereof which have nematicidal effect (ii) an agriculturally acceptable carrier oil and (iii) an emulsifier.... Agent: Townsend And Townsend And Crew, LLP

20090263521 - Composition for the treatment of cancers and inhibition of metastasis containing extracts or fractions of the magnolia obovata: The present invention relates to a composition containing the extracts of Magnolia obovata Thunberg or fractions thereof for the prevention and treatment of cancer and for the inhibition of metastasis. Particularly, the extracts of Magnolia obovata Thunberg fruits and floral buds extracted with water, alcohol or a mixture thereof as... Agent: Lucas & Mercanti, LLP

20090263522 - Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or... Agent: Mcdermott Will & Emery LLP

20090263523 - Enhancer of cholinesterase activity: The invention provides an enhancer for cholinesterase. An enhancer comprising Gam Arabic as an active ingredient is useful for preventing and/or treating a decreased cholinesterase activity due to liver damage or inhibition of cholinesterase as a side effect of various agents.... Agent: Wenderoth, Lind & Ponack, L.L.P.